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Epitope tagging in metazoans is an important tool fr biochemical analyses and is 
generally accomplished by using trans-genes with in-frame epitope tags.  However, 
protein levels from trans-genes are rarely representative of native levels.  To overcome 
the shortcomings using trans-genes, epitope tags were introduced by homologous 
recombination technology, termed CLEP tagging (Chromosomal Locus EPitope tagging), 
immediately upstream of the stop codon of targeted g nes in chicken B cell line DT40 
and mouse embryonic stem (ES) cells.  I first demonstrated the feasibility and promise 
of this technique in DT40 cells by purifying low abundance polypeptides and factors 
loosely associated with the SmD3 protein, a core protein participating in pre-mRNA 
splicing and mRNA turnover, with a TAP (tandem affinity purification) tag.  Glycerol 
gradient separation was performed to further characte ize the SmD3-associated protein 
complexes from the 200S fractions, corresponding to the supraspliceosomes.  The 
purification included all five spliceosomal snRNAs.  Most known snRNP-associated 
 viii  
proteins, 5’ end binding factors, 3’ end processing factors, mRNA export factors, 
hnRNPs, and other RNA binding proteins were identified from the protein components.  
Intriguingly, the purified supraspliceosomes also cntained a number of structural 
proteins, nucleoporins, chromatin remodeling factors, and several novel proteins that 
were absent from splicing complexes assembled in vitro.  I showed that the in vivo 
analyses provide a more comprehensive list of polypeptides associated with pre-mRNA 
splicing apparatus as well as those that coupled transcription to the pre-mRNA processing 
steps.  With similar techniques, the TAP tag was inserted into the chromosomal locus of 
a pre-mRNA splicing factor component, mSART-1 in live mice.  Surprisingly, a 
profound autoimmune response was induced in homozygous-modified mice, due likely to 
an inappropriate stimulation of the immune system.  I believe these mice will serve as a 
valuable tool for the studies of mammalian autoimmune diseases, especially those 
resulting from the generation of autoantibodies against RNP components.  
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Chapter 1: Introduction 
1.1 GENE EXPRESSION IN EUKARYOTES 
1.1.1 Overview  
Gene expression in eukaryotes is a highly dynamic and regulated process.  In 
order to have proper gene expression in eukaryotic cells, RNA polymerase II (RNA Pol 
II) transcripts undergo several coordinated processing teps before the mature mRNA is 
exported to the cytoplasm for translation.  These pre-mRNA processing steps include 
capping of the pre-mRNA with a 7-methyl guanosine cap structure at the 5’ end, intron 
removal by the spliceosome, RNA editing, and cleavage nd polyadenylation of pre-
mRNA by the 3’ end processing machinery.  Studies have shown that these steps are 
coupled to each other and occur co-transcriptionally on the nascent transcripts 
[Illustration 1.1, for review, see (Howe, 2002; Maniatis and Reed, 2002; McCracken et 
al., 1997)]. 
1.1.2 The carboxyl-terminal domain (CTD) of RNA Pol II: an assembly platform for 
pre-mRNA processing factors 
The carboxyl-terminal domain (CTD) of the RNA Pol II plays an important role 
for the recruitment and regulation of processing factors.  The CTD is composed of 
heptad consensus repeats, YSPTSPS, which is repeated 27 times in yeast and 52 times in 
humans.  Serine 2 (Ser2) and Serine 5 (Ser5) residus within the repeats are 
phosphorylated during transcription.  The pattern of the CTD phosphorylation changes 
as transcription proceeds (Komarnitsky et al., 2000).  Ser5 phosphorylation is detected 
primarily at the promoter while Ser2 phosphorylation s seen only in coding regions.  In 
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yeast, the recruitment of Kin28 kinase, a subunit of transcription factor TFIIH, 
phosphorylates Ser5 of the CTD at the promoter (Hengart er et al., 1998) and as 
elongation proceeds, phosphorylation of the CTD on Ser2 by Ctk1 increases (Cho et al., 
2001).  In higher eukaryotes, several C-terminal kinases (CTK) have been found to 
catalyze phosphorylation and their recruitment and ffinity are affected by the position of 
the targeted repeats within the CTD and the phosphorylation state of the neighboring 
residues (Palancade and Bensaude, 2003; Ramanathan et al., 2001).  The CTD deletions 
do not inactivate transcription but prevent efficient co-transcriptional capping, splicing 
and 3’ end cleavage and polyadenylation (Fong and Bentley, 2001).  Moreover, 
dynamic site-specific phosphorylation and dephosphorylation of the CTD is critical for 
coupling RNA Pol II transcription to the processing factors (Maniatis and Reed, 2002). 
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Illustration 1.1 Coupled interaction in gene expresion 
The C-terminal domain (CTD) functions as an assembly platform and regulator for co-
transcriptional recruitment of pre-mRNA processing factors.  The 5’ capping enzymes, 
guanylyltransferase (GT) and 7-methyltransferase (MT), splicing factors (SF) and 3’ end 
cleavage/polyadenylation factors (C/P) are recruited via the CTD.  Dash arrows indicate 
that all the processing pathways are coupled with each other for proper gene expression.  
Exon-Exon junction complexes (E) formed during splicing are important for mRNA 
export. 
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1.1.3 Coupling between transcription and the pre-mRNA processing machinery 
1.1.3.1 5’ end capping 
Capping of the nascent transcripts at the 5’ end protects them from degradation.  
This step involves 3 enzymes, the guanylyltransferae, the 7-methyltransferase, and the 
RNA triphosphatase.  Different phosphorylated/dephos rylated forms of the CTD 
regulate the recruitment of the capping enzymes.  Ser5 phosphorylation on the CTD is 
necessary for the recruitment of the capping enzymes, guanylyltransferase and 7-
methyltransferase.  Subsequent Ser5 dephosphorylatin in early elongation results in the 
release of the guanylyltransferase (Komarnitsky et al., 2000; Schroeder et al., 2000).  
Ser2 on the CTD is then phosphorylated, leading to the recruitment of the RNA 
processing factors required for the subsequent steps (Cho et al., 2001).  Capping 
enzymes also cooperate with transcription factors t timulate elongation and promoter 
clearance (Mandal et al., 2004). 
1.1.3.2 Recruitment of the spliceosome 
Several splicing factors have been shown to be coupled to the transcription 
machinery.  The U1 snRNP associates with transcription elongation factors at the time 
of recognition of the 5’ splice site of the intron (Kotovic et al., 2003).  The U1 snRNP-
associated splicing factor Prp40 (Kao and Siliciano, 1996), which is proposed to bring the 
5’ and the 3’ splice sties together during splicing (Berglund et al., 1997), interacts with 
phosphorylated CTD (Morris and Greenleaf, 2000).  Elongation factor, TAT-SF1 and 
CUS2 (yeast homolog), interacts with splicing factors and regulates the assembly of 
splicing complexes (Fong and Zhou, 2001; Yan et al., 1998).  SR proteins, important for 
both constitutive and alternative splicing (Graveley, 2000), have been shown to interact 
with the transcriptional coactivator PGC-1 (Cramer et al., 1999), suggesting a connection 
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between transcription and alternative splicing (Goldstrohm et al., 2001).  In addition, the 
cap-binding complex has been shown to interact with splicing factors and promote the 
recognition of the proximal 5’ splice site (Colot eal., 1996; Lewis et al., 1996).  
Coupling of splicing factors to transcription is pro osed to concentrate splicing factors on 
nascent transcripts, allowing constitutive and alternative splicing to occur efficiently and 
accurately (Maniatis and Reed, 2002). 
1.1.3.3 3’ end formation 
The formation of the 3’ end of mRNA occurs in two steps.  First, the nascent 
transcript is cleaved 20-30 bases downstream of a cnserved poly(A) site, AAUAAA, by 
the cleavage and polyadenylation factors.  Second, poly(A) polymerase adds a poly(A) 
tail to the 3’ OH of the nucleotide at the site of mRNA cleavage.  It has been shown that 
3’ end processing factors, CstF50, Ydh1, Yhh1, and R a14 bind to the CTD (Proudfoot, 
2004).  Splicing and 3’ end formation have also been shown to be coupled (Vagner et 
al., 2000).  Splicing factors are able to interact with poly(A) polymerase and promote 
3’end formation; polyadenylation, in turn, can stimulate splicing [reviewed in (Berget, 
1995)]. 
1.1.3.4 Recruitment of mRNA export factors 
After transcription termination, the mature mRNA and RNA Poll II are released 
from the DNA template.  The mature RNA is then transported to nuclear pores for 
export to the cytoplasm.  Evidence has shown that mRNAs generated by splicing are 
more efficiently exported than their intronless counterparts transcribed from DNA, even 
when they are identical in sequence (Luo and Reed, 1999).  Protein complexes recruited 
adjacent to the exon-exon junctions during splicing, are assembled into a unique complex 
and critical to couple splicing to mRNA export (Le Hir et al., 2000).  UAP65, a splicing 
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factor required for early spliceosome assembly, is also a protein component in the exon 
junction complex that couples splicing to mRNA export (Luo et al., 2001; Zhou et al., 
2000).  UAP65 interacts directly with the mRNA transport factor, ALY, which then 
interacts with the nuclear export adapter TAP, delivering the mRNA to the nuclear pore 
for export (Strasser and Hurt, 2001).  Links between transcription, 5’ end capping, 
splicing, 3’ end formation and export ensure all the steps are timely coordinated for 
proper gene expression. 
1.2 PRE-MRNA SPLICING AND THE SPLICEOSOME ASSEMBLY  
1.2.1 Small nuclear RNAs (snRNA) 
1.2.1.1 The discovery of snRNAs 
The existence of low molecular weight RNA, 90-400 nucleotides long, which 
sedimented in the 4-8S region of a sucrose gradient was reported in the 1960s (Hodnett 
and Busch, 1968; Moriyama et al., 1969; Muramatsu e al., 1966; Prestayko and Busch, 
1968).  These small RNAs were divided into small nucleolar, small nuclear and small 
cytoplasmic RNAs based on their cellular localization.  A subset of these small RNAs, 
rich in uridylic acid was first identified from nucleoli of Novikoff hepatoma cells 
(Muramatsu et al., 1966).  This RNA had an uridine-rich base composition, different 
from that of the ribosomal RNA (rRNA) and transfer RNA (tRNA) and was designated 
U-RNA.  By sedimentation, chromatography, and terminal nucleoside analysis, six U-
RNA (U-small nuclear RNA, U-snRNA), U1 snRNA (Reddy et al., 1981b; Reddy et al., 
1974), U2 snRNA (Shibata et al., 1975), U3 snRNA (Reddy et al., 1979; Reddy et al., 
1980), U4 snRNA (Reddy et al., 1981a), U5 snRNA (Krol et al., 1981), and U6 snRNA 
(Epstein et al., 1980) were identified and well characterized from nuclei.  U3 is 
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nucleolar while U1, U2, U4, U5, and U6 are nucleoplasmic.  snRNAs are present at 0.2-
1 106 molecules per cell.  The sequencing of snRNAs led to the discovery of cap 
structures (Reddy et al., 1974), followed by studies on cap structure of messenger RNA 
(mRNA) and viral RNA (Rottman et al., 1974; Shatkin, 1976).  
1.2.1.2 The biogenesis of snRNAs 
With the exception of U6, the U1, U2, U3, U4, and U5 are synthesized by RNA 
polymerase II, acquiring a monomethyl guanosine (7mGpppG) cap and their primary 
transcripts are extended far beyond the 3’ end of the mature RNA (Busch et al., 1982; 
Eliceiri, 1980).  They are compacted into a large export complex, including cap-binding 
proteins and CRM1/RanGTP for export to the cytoplasm (Kiss, 2004).  In the 
cytoplasm, the snRNAs associate with the survival of m tor neuron (SMN) complex 
(Paushkin et al., 2002), which directs the assembly of the seven related Sm proteins 
SmB/B’, SmD1, SmD2, SmD3, SmE, SmF, and SmG, which assemble into a 
heteroheptameric ring complex and bind to the conserved Sm-binding site within the 
snRNA (Luhrmann et al., 1990; Will and Luhrmann, 2001).  Binding of the Sm proteins 
is important for hypermethylation of the 7mG cap to 2,2,7-trimethylguanosine (TMG) 
cap (Mattaj, 1986; Mouaikel et al., 2002; Plessel et al., 1994), as well as exonucleolytic 
cleavage of 3’ sequences.  Both the assembled Sm core and TMG provide signals for the 
efficient import of the newly assembled small nuclear ribonucleoproteins (snRNPs).  
The snRNPs are then imported back to the nucleoplasm with the help of snurportin and 
importin β (Palacios et al., 1997) for further modification in Cajal bodies (Jady et al., 
2003).  U6, synthesized by RNA polymerase III, carries a γ–monomethylphosphate 
(mpppG) cap structure (Singh and Reddy, 1989).  A heteroheptameric ring of seven Sm-
like proteins, Lsm2, Lsm3, Lsm4, Lsm5, Lsm6, Lsm7 and Lsm8, binds to the 3’-terminal 
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UUUU sequence of U6 snRNA (Achsel et al., 1999).  Binding of the Lsm proteins is 
critical to direct the modification of U6 in the nucleolus (Gerbi et al., 2003).  The 
biogenesis of U6 is confined to the nucleus (Gerbi t al., 2003; Kiss, 2004). 
1.2.2 Small nuclear ribonucleoproteins (snRNP) 
1.2.2.1 The isolation of snRNPs 
The snRNAs are not present as naked RNA molecules in the nucleoplasm but 
exist in specific RNA-protein complexes called small nuclear ribonucleoprotein (snRNP) 
particles (Lerner and Steitz, 1979; Raj et al., 1975).  Isolation of the U1 and U2 snRNPs 
was first achieved by Raj et al. using Sepharose gel filtration and sucrose density gradient 
and 10 proteins were shown to be present in the complexes (Raj et al., 1975).  The 
discovery of an autoimmune reaction between several classes of eukaryotic snRNPs and 
autoantibodies from sera of patients with rheumatic diseases such as systemic lupus 
erythematosus, mixed connective tissue diseases, scleroderma, and Sjögren’s syndrome 
has facilitated the structure and localization analyses of snRNP particles.  Lerner and 
Steitz showed that anti-Sm antibodies immunopurified the U1, U2, U4, U5, and U6 
snRNP particles whereas anti-U1 RNP antibodies preci itated only U1 snRNP (Lerner 
and Steitz, 1979).  The protein components are essential for antigenicity and antigenic 
determinants of the snRNP are highly conserved between species.  Another two classes 
of small ribonucleoproteins, Ro/SSA and La/SSB are lso detected by antibodies 
associated with Sjögren’s syndrome and lupus erythematosus (Lerner et al., 1981).  
Immunological methods offer a useful approach for snRNP purification; however, it is 
difficult to recover snRNPs in a native structure from the antibody affinity columns. 
In order to analyze the native structure and functio  of snRNPs, The Lührmann 
laboratory developed a procedure for the isolation of snRNPs on a preparative scale using 
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antibodies against the TMG cap, anti-m3
2,2,7 G antibodies, and purified proteins by 
affinity chromatography with anti-m3
2,2,7 G IgG (Bringmann et al., 1983).  Eluting the 
antibody-bound snRNPs from the column with excess nucleoside m3
2,2,7 G or 7mG 
maintains the native structure of the snRNPs. 
1.2.2.2 A link between snRNPs and splicing 
The first study to implicate the role of snRNPs in pre-mRNA processing pathways 
was reported by Sekeris et al. who showed that the snRNAs co-sediment with large 
particles that bind hnRNA (Sekeris and Niessing, 1975).  In the early 1980s, Lerner t 
al. reported that snRNAs were present in all eukaryotes and are well conserved through 
evolution.  snRNPs were present in highest abundance in metabolically active cell types, 
such as liver cells and most importantly, the 5’ end sequence of the U1 snRNA is 
complementary to 5’ splice junctions in mRNA precursors (Lerner et al., 1980).  This 
was the first demonstration that an RNA-RNA interaction is important for molecular 
recognition.  Another clue to the role of the snRNPs in splicing came from the evidence 
that splicing was inhibited in HeLa cell nuclei when they are preincubated with anti-Sm 
or anti-RNP antibodies (Yang et al., 1981).  Further studies of the structure and function 
of snRNPs have revealed different roles of distinct snRNPs in the pre-mRNA splicing 
reaction as described in the text below. 
1.2.3 The splicing reaction 
1.2.3.1 Pre-mRNA splicing machinery, spliceosome 
The coding sequences, exons, in most primary transcipt  of RNA polymerase II 
are interrupted by intervening sequences, IVSs, or introns.  Introns have to be removed 
from pre-mRNA in a process called pre-mRNA splicing to generate the mature mRNA 
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before it is exported from the nucleus to the cytoplasm where it is translated into protein 
(Sharp, 1994).  The first evidence revealing that coding regions were interrupted was 
found by the Sharp and the Roberts laboratories in 1977 (Berget et al., 1977; Chow et al., 
1977).  They showed the DNA template of adenovirus major late was not able to form a 
smooth hybrid with its mRNA, indicating that some portions of the sequence, later 
termed introns, were missing from the mRNA.  In addition, three adenovirus major late 
mRNAs shared a common 5’ end.  
The machinery that splices pre-mRNA is called the spliceosome which is 
comprised of hundreds of proteins and five small nuclear RNAs (U1, U2, U4, U5, and 
U6) assembled into small nuclear ribonucleoproteins (snRNPs).  U1, U2, U4, and U5 
are transcribed by RNA polymerase II, sharing two common features, the 5’-terminial 
TMG cap and highly conserved Sm site [RA(U)4GR] flanked by two stem-loop structures 
(Luhrmann et al., 1990).  U6 is transcribed by RNA polymerase III, containing a γ-
mono-methyl-phosphate cap and no Sm site.  Sm proteins are common proteins in U1, 
U2, U4, U5 snRNPs and are essential for 5’ hypermethyla ion of the 7mG cap to 2, 2, 7-
trimethylguanosine and re-import of the mature snRNAs back to the nucleus.  Other 
proteins are found associated with specific snRNPs, involved in different dynamic 
interaction with pre-mRNA.  
1.2.3.2 Splicing signals 
The splicing signals are consensus sequences located at he exon/intron junctions 
[(Stephens and Schneider, 1992) and Illustration 1.2].
5’-AG/GURAGU-------intron------YNCURAY-(Y)n---------YAG/-3’ 
The 5’ splice site conforms to the consensus sequence AG/GURAGU where the 
slashes are the exon/intron borders, R is any purine, a d Y is any pyrimidine.  The 3’ 
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splice site is characterized by the sequence YAG.  The first two and the last two bases, 
underlined GU and AG, respectively, of the intron are lmost invariant.  In addition to 
the consensus sequences at the 5’ and 3’ end of the in rons, another two sequence 
elements, the polypyrimidine tract [(Y)n] and branchpoint sequences (YNCURAY) are 
also important for accurate splicing (Kramer, 1996).  The polypyrimidine tract is a 
stretch of pyrimidine residues preceding the 3’ splice site (Kramer, 1996).  It is 
important for the definition of the 3’ splice site and the recruitment of proteins for the 
earliest stage of spliceosome assembly.  The branchpoint sequence YNCURAY is 
located 18-40 nucleotides upstream of the 3’ splice sit  and the branchpoint adenine 
nucleotide, the site of branch formation, is underlin d (Zhuang et al., 1989).  In the yeast 
Saccharomyces cerevisiae, this sequence is more highly conserved: and is almost always 
UACUAAC whereas the sequence is more variable in higher eukaryotes.  All of these 
consensus sequences are important for proper splicing and gene expression. 
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Illustration 1.2 Splicing signals and the two catalytic steps of pre-mRNA splicing 
(A) The pre-mRNA is represented by two boxes, exon 1 and exon 2 connected by a line, 
intron sequences.  The conserved splicing signals within the 5’ splice site [GU], 3’ 
splice site [AG], branchpoint [YNCURAY], and pyrimidine tract [(Y)n] are highlighted.  
The arrows represent the nucleophilic attack of the hydroxyl group (OH) on the splice 
junction.  (B) The first step of splicing results in the 5’ splice site cleavage and the lariat 
intermediate formation.  (C) The second step results in the 3’ splice site cleavage, 
forming a lariat intron and concurrent exon ligation. 
 
 
1.2.3.3 The catalysis of splicing 
Intron excision involves 2 transesterification step.  The first step of the reaction 
is initiated by a nucleophilic attack of the 2’ hydroxyl group of the adenosine at the 
branch site on the phosphodiester bond at the 5’ splice site, yielding the 5’ exon and the 
lariat intermediate.  The lariat intermediate is formed by the guanosine at the 5’ 
terminus of the intron covalently linked to the branch site adenosine in an unusual 2’-5’-
A 
B 
C 
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phosphodiester bond.  In the second step, the free 3’-hydroxyl group on the 5’ exon 
attacks the phosphodiester bond between the intron and the 3’ exon, resulting in the 
concurrent ligation of the exons and the release of a lariat-shaped intron (Padgett et al., 
1984; Ruskin et al., 1984).  
1.2.3.4 The spliceosome assembly cycle  
Studies have showed that the spliceosome is assembled in a stepwise fashion 
(Illustration 1.3).  First, the U1 snRNP interacts with the 5’ splice site via base pairing 
of the 5’ end of U1 snRNA to the conserved sequences at the 5’ splice site.  The 
interaction between U1 snRNP and pre-mRNA forms the early (E) complex (Ruby and 
Abelson, 1988; Seraphin et al., 1988; Zhang and Rosbash, 1999; Zhuang and Weiner, 
1986).  This stage occurs in an ATP- and temperature-independent manner. Some 
protein components are recruited in the E complex for the initial recognition event.  For 
example, SR proteins are incorporated into the spliceosome at the time of E complex 
formation and promote the binding of U1 snRNP to 5’ splice sites and splice site 
selection (Jamison et al., 1995; Kohtz et al., 1994; Zahler and Roth, 1995).  U2 snRNP 
auxiliary factor (U2AF), composed of two subunits of 35 and 65 kDa, binds to the 
polypyrimidine tract (Zamore and Green, 1989).  It is not only important for U1 snRNP 
recruitment to the 5’ splice site but is also essential for the association of between U2 
snRNP and the pre-mRNA (Forch et al., 2003; Ruskin et al., 1988; Zamore and Green, 
1989).  Splicing factor 1 (SF1) specifically recognizes the branch point sequence in the 
pre-mRNA facilitating the association between U2 snRNP and the pre-mRNA (Berglund 
et al., 1997; Liu et al., 2001).  Stable interaction between the U2 snRNP and the 
branchpoint sequence forms of the pre-mRNA complex A (Parker et al., 1987; Zhuang 
and Weiner, 1989).  This step, as well as many subsequent steps, is ATP-dependent 
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(Cheng and Abelson, 1987; Pikielny and Rosbash, 1986).  The U4/U6U5 tri-snRNP 
then joins in the B complex and forms a mature spliceosome, catalyzing two steps of 
transesterification for intron excision in the C complex (Kramer, 1996; Padgett et al., 
1984; Ruskin et al., 1984).  
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Illustration 1.3 The classical pre-mRNA spliceosome assembly cycle 
The pre-mRNA is represented by two boxes, exon 1 and exon 2 connected by a line, 
intron sequences.  The conserved sequences are highlig ted and the U1, U2, U5, U4/U6, 
U4/U6•U5 snRNPs are represented as purple spheres.  Base pairing interactions 
between the pre-mRNA and the snRNAs are indicated by the hatched markings.  The 
ATP and 8 helicases important for RNA arrangement are denoted. 
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1.2.3.5 Structure and composition of snRNPs 
The five spliceosomal snRNPs (U1, U2, U4, U5, and U6), each containing a small 
stable RNA bound by several proteins, plus numerous ther less stably-associated 
splicing factors are involved in pre-mRNA splicing reaction.  U4 and U6 snRNA are 
extensively base-paired and package into a single ribonucleoprotein particle while U1, 
U2, and U5 snRNPs can be found in distinct particles (Maniatis and Reed, 1987).  With 
improved isolation techniques, greater numbers of polypeptides have been identified as 
additional particle-specific proteins. 
The U1 snRNP, which sedimented as a 10S particle, was isolated independently 
from the laboratories of Steitz and Lührmann (Bringmann and Luhrmann, 1986; 
Bringmann et al., 1983; Hinterberger et al., 1983).  It contains the common Sm proteins, 
SmB’, SmB, SmD, SmD’, SmE, SmF, SmG and additional three unique polypeptides, 
U1-70K, U1-A, and U1-C. 
The 17S U2 snRNP was identified from Lührmann’s labor tory containing the 
common Sm proteins, and the U2A’, U2B’’, SF3a, and SF3b components (Behrens et al., 
1993a; Behrens et al., 1993b).  The integrity of the U2 snRNP appears to be very 
sensitive to salt concentration as it was first isolated as 12S particle without SF3a and 
SF3b components (Bringmann and Luhrmann, 1986). 
The 25S U4/U6•U5 tri-snRNP particle joins the spliceosome as a tripartite 
particle (Behrens and Luhrmann, 1991).  The tri-snRNP contains additional 
polypeptides, U4/U6•U5-110K, U4/U6•U5-65K, U4/U6•U5-61K, and U4/U6•U5-15.5K, 
that are not associated with the 20S U5 (U5-220K, U5-200K, U5-116K, U5-102K, U5-
100K, U5-40K and U5-15K) (Bach et al., 1989) or 10S U4/U6 snRNPs (U4/U6-90K and 
U4/U6-60K).  The isolated U5 and U4/U6 RNPs themselves can not assemble into the 
25S particle without the help of additional polypeptides released from the tri-snRNP by 
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micrococcal nuclease treatment.  Moreover, addition of U5 and U4/U6 snRNPs cannot 
restore the splicing activity in extracts devoid of 25S tri-snRNP particle (Utans et al., 
1992). 
1.2.3.6 ATP-dependent RNA helicases 
Temporal and spatial regulation of RNA and protein conformational 
rearrangements in the pre-mRNA splicing machinery rquires energy in the form of ATP 
at multiple steps (Madhani and Guthrie, 1994).  Eight RNA helicase in the yeast S.
cerevisiae, Prp5p, Sub2p, Prp28p, Brr2p, Prp2p, Prp16p, Prp22p, and Prp43p, containing 
sequence motifs of the DEAD/H family have been well characterized (Illustration 1.3). 
Prp5p contains distinct U1- and U2-interacting domains that are required for U2 snRNP 
association (Dalbadie-McFarland and Abelson, 1990; Xu et al., 2004), a reaction 
coordinated by Sub2p (Libri et al., 2001).  During catalytic activity, Prp28p destabilizes 
the interaction between U1 snRNA and the 5’ splice sit and Brr2p unwinds the U4/U6 
helix, allowing U6 snRNA to replace the U1 snRNA at the 5’ splice site and to base-pair 
with U2 snRNA (Raghunathan and Guthrie, 1998; Staley nd Guthrie, 1999).  Prp2p 
mediates the rearrangement of the first catalytic step of splicing (Chen and Lin, 1990; 
Kim and Lin, 1996) while Prp16p promotes the second step of splicing (Schwer and 
Guthrie, 1991; Schwer and Guthrie, 1992).  Prp22p has dual roles in pre-mRNA 
splicing; it is required for the second step of splicing in an ATP-independent manner and 
release of the mRNA from the spliceosome and initiation of spliceosome disassembly in 
an ATP-dependent manner (Company et al., 1991; Schwer and Gross, 1998).  Finally, 
Prp43p is involved in the snRNP recycling pathways which are not well understood 
(Arenas and Abelson, 1997; Martin et al., 2002).  
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1.2.4 Large nuclear ribonucleoprotein particle, the pre-mRNA processing machine 
Consistent with the view of co-transcriptional recruitment of pre-mRNA 
processing factors, other investigators have shown that mammalian nuclear pre-mRNA is 
assembled into large nuclear ribonucleoprotein particles (lnRNP), called 
supraspliceosomes (Azubel et al., 2004; Muller et al., 1998; Sperling et al., 1985) or 
polyspliceosomes (Wassarman and Steitz, 1993).  A rema kable feature of the lnRNP 
particles is that they package pre-mRNA transcripts of very different sizes and of 
different numbers of introns; however they are compacted into a complex with a unique 
size and hydrodynamic properties that sediment at ~200S in sucrose gradients.  The 
lnRNP is thought of as a nuclear pre-mRNA processing machine with all of the U 
snRNPs required for pre-mRNA splicing, Ser/Arg-rich (Blanton et al.) proteins, A-to-I 
editing enzymes, cap-binding complex, and 3’-end-processiong components (Raitskin et 
al., 2002; Yitzhaki et al., 1996).  Based on the structure and mass determination by 
scanning transmission electron microscopy, the lnRNP particle has an average mass of 
21.1 MDa and is proposed to have one to eight repeating spliceosomal substructures, 
each with a mass of 4.8MDa (with a median of four), and the fifth substructure with a 
mass of 1.9 MDa containing 5’-end capping and 3’-polyadenylation activities (Muller et 
al., 1998).  The pre-mRNA is looped around this huge particle for intron removal and 
processing.  This lnRNP assembly model is hypothesized to result in better efficiency 
and specificity of recognition of large introns, providing a machine for an accurate and 
regulated processing of pre-mRNAs. 
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1.3 AFFINITY TOOLS FOR THE PURIFICATION OF RIBONUCLEOPRO TEINS IN YEAST  
1.3.1 Application of affinity chromatography for the purification of epitope-tagged 
proteins 
Affinity chromatography is a powerful tool for the purification of biologically 
active multi-protein complexes, for protein compositi nal, structural and functional 
studies.  In some cases, such as fluorescent tags, they can also provide information 
regarding the dynamics and localization of biological molecules inside the cells.  In this 
technique, a fragment of DNA coding for the tag of interest is cloned in frame with the 5’ 
or 3’-terminus of the targeted gene.  The expressed fusion protein containing the tag can 
be affinity-purified by its cognate binding partner immobilized onto a solid-phase matrix.  
Affinity tags range from small peptides to large proteins.  The selection of the 
appropriate affinity chromatography system and purification condition is based on the 
nature of the application.  One of these affinity tags, the tandem affinity purification tag 
(TAP tag), has been used to purify multi-protein complexes from yeast with high 
specificity and efficiency (Puig et al., 2001).  The TAP tag contains two affinity 
cassettes, the Staphylococcus aureus protein A (Pro A) and a calmodulin binding peptide 
(CBP) separated by a TEV (tobacco etch protease) protease cleavage site.  Cellular 
extracts are passed through a non-specific IgG matrix to which Pro A binds tightly for the 
first step of purification, followed by TEV protease treatment to release the bound 
material.  The eluate is then incubated with calmodulin-coated beads in the presence of 
calcium.  After washing away the contaminants and TEV protease, the purified protein 
complex is eluted with an EGTA-containing buffer, which chelates the calcium, releasing 
the complex from the matrix. 
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1.3.1.1 Gene targeting and affinity chromatography in yeast 
In yeast cells, the best and fastest way to generate an epitope-tagged protein is to 
use a PCR-based genomic tagging approach (Petracek and Longtine, 2002).  Briefly, 
PCR fragments containing the epitope-tag sequence ad selectable markers with flanking 
DNA sequence homologous to the sequence of the targted locus are transformed into the 
yeast cells.  The highly efficient homologous recombination system in yeast ensures that 
most of the time, the epitope tag is inserted into the targeted gene in the chromosome at 
the target site.  Yeast cells expressing the epitope- agged protein are selected on dropout 
or drug-containing media, depending on the selectable markers.  Homologous 
recombination between transformed DNA and the genome was first observed by two 
groups, the Beggs laboratory and the Fink Laboratory in the late 1970s (Beggs, 1978; 
Hinnen et al., 1978).  Many factors such as the length of homology at the ends, circular 
versus linear DNA fragments, and different chromosomal regions influence the frequency 
of homologous recombination (Rothstein, 1991).  Tagged protein expression by gene 
targeting has been widely used for protein localization and components studies in yeast, 
on a genomic scale, as well as for the purification f low-abundance RNPs 
(Ghaemmaghami et al., 2003; Huh et al., 2003; Stevens, 2000). 
1.3.1.2 Purification of protein complexes from metazoan cells 
In vertebrate and mammalian cells, epitope-tagging in the chromosomal locus is 
inefficient due to fact that the rate of homologous recombination is extremely low.  
Analogous purifications of proteins or large complexes are based either on an ectopically 
expressed trans-gene containing an epitope tag, or the use of the relatively expensive 
monoclonal antibodies.  Generally, the gene of interest is regulated by the human 
cytomegalovirus (CMV) immediate-early regulatory sequ nce called CMV promoter.  
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However, spatial and temporal expression of the native gene locus is lost under an active, 
constitutive and heterologous promoter; furthermore, th  constructs integrate into the 
chromosome randomly and the site of integration strongly affects the expression level of 
the epitope-tagged protein.  Equally importantly, a single cDNA is used, and the 
alternative splicing program for the gene of interest is completely lost.   
1.3.2 Purification of salt stable yeast snRNPs 
Purification and identification of the snRNPs from ammalian cells and yeast 
were originally based on anti-Sm antibodies, anti-U1 snRNP antibodies, and a 
monoclonal antibody against the TMG cap portion of the snRNAs.  However, due to the 
low abundance of snRNP proteins in yeast, isolation of intact splicing complexes is 
extremely difficult.  Stevens et al. developed a dual affinity chromatography cassette 
which can be used to purify stable protein complexes from yeast by epitope tagging any 
gene at its endogenous chromosomal locus (Stevens, 2000; Stevens and Abelson, 1999).  
The dual affinity cassette consists of a polyhistidne [(His)8] sequence followed by two 
repeats of the polyoma epitope (Stevens and Abelson, 1999).  Yeast U4/U6·U5 tri-
snRNP was purified by a 2-step purification using polyoma-agarose chromatography and 
Ni-NTA resin with subsequent glycerol gradient sedimentation.  Yeast U5 snRNP and 
U6 snRNP were purified by polyoma-agarose chromatogr phy using strain containing a 
polyoma-tagged BRR2 gene and PRP24 gene respectively (Stevens, 2000; Stevens et al., 
2001).  The newly identified associated factors were fu ther analyzed biochemically and 
genetically to determine their functional role in splicing (Stevens et al., 2001).  Yeast 
U1 snRNP was isolated by the Lührmann laboratory by anti-TMG-cap immunoaffinity 
and subsequent nickel-NTA chromatography using a str in containing hexahistidine 
[(His)6] tagged U1-70K at its N-terminus (Neubauer et al., 1997) and the yeast U2 snRNP 
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was partially purified in the Seraphin laboratory from TAP tagged U2A’ protein (Behrens 
et al., 1993b; Caspary et al., 1999) Due to the salt-sensitive association of the SF3a and 
SF3b components (Behrens et al., 1993b) the intact U2 snRNP has never been purified 
from yeast. 
Interestingly, Stevens et al. have noticed that during the purification of the yeast 
U4/U6U5 tri-snRNP, there are salt-dependent changes in the characteristics of the 
snRNP complexes (Stevens et al., 2002).  When purifying the tri-snRNP from polyoma 
epitope-tagged Prp4p at 250 mM KCl, only those snRNAs, U4, U5, U6, most tightly 
associated with the protein were immunopurified.  As the salt concentration was 
lowered to 150 mM, they observed a U2 4/U6U5 tetra-snRNP which sedimented at ~ 
30S in glycerol gradients.  When the salt concentration was reduced to 50 mM during 
purification, a U1U2U4/U6U5 penta-snRNP was observed which sedimented at ~45S.  
Based on previous studies, discrete U1, U2, and U4/U6U5 snRNP particles have been 
purified under high salt conditions which are not cmpatible with optimal splicing 
condition in vitro (Lin et al., 1985).  Isolated nuclei were extracted under high salt 
conditions and buffer containing high salt concentration was used to reduce background 
non-specific binding during the one-step antibody affinity purification.  Under stringent 
conditions, only the most tightly associated protein complexes were immunopurified.  It 
is likely that the proteins that are not present at high salt concentration, but are present 
under the more splicing-friendly conditions, do participate in splicing. 
1.3.3 The discovery of penta-snRNP 
Stevens et al. showed that the 45S penta-snRNP particle contained 85% of all 
know yeast splicing factors and exhibited splicing activity when supplemented with 
micrococcal nuclease (MN) treated extract (Stevens et al., 2002).  They proposed that 
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the penta-snRNP functions as a pre-formed non-dissociating particle by mixing 
experiments, indicating that endogenous penta-snRNPs are the major precursors to 
spliceosomes in yeast extracts.  
Whether snRNPs join the splicing reaction stepwise or as an assembled complex, 
or both, is still a debatable issue.  However, several groups have evidence suggesting the 
preassembled particle for splicing.  Antibodies against snRNP proteins such as Prp4p 
(Banroques and Abelson, 1989), Prp6p (Abovich et al., 1990), Prp18p (Horowitz and 
Abelson, 1993), and Brr2p (Raghunathan and Guthrie, 1998) are able to 
immunoprecipitate all five snRNAs in stoichiometric amounts under salt conditions 
around 50-100 mM, optimal for splicing reaction in yeast.  However, as the salt 
concentrations are raised to 200-300 mM, only the RNAs most tightly associated with the 
proteins are detected.  Guialis et al. (Guialis et al., 1991) and Moraitou et al. (Moraitou 
et al., 1998), separately showed a penta-snRNP-like particle from mammalian cells that 
contains all five snRNAs.  
The Sperling group isolated a native spliceosome complex from 
supraspliceosomes by hybridizing the supraspliceosome with a DNA oligonucleotide 
complementary to the consensus 5’ splice site sequence, followed by RNase H digestion 
(Azubel et al., 2006; Azubel et al., 2004).  Visualiz tion by cryo-electron microscopy, 
and 3D model reconstruction showed a globular shape consisting of 2 distinct subunits, 
one large and one small, connected to each other leaving a tunnel in between (Azubel et 
al., 2004).  Based on the mass and volume calculation, he larger subunit is a suitable 
candidate for the penta-snRNP particle while the small subunit is proposed to contain 
other pre-mRNA processing factors and the tunnel is where the pre-mRNA passes 
through.  They further proved that the native spliceosome, containing all five snRNAs, 
is splicing competent (Azubel et al., 2006).  
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1.4 DISSERTATION OBJECTIVES  
Epitope tagging technology has enhanced the tool kit of the molecular biologist 
by allowing the facile detection, tracking and purification of virtually any polypeptide in 
any model organism.  Adding epitope tags to proteins is generally accomplished in 
metazoan cells using ectopically expressed, trans-ge es.  I began my dissertation work 
with the intention of developing a better biochemical tool for purification which 
circumvents the shortcomings of trans-genes by introducing the epitope tag into the 
native chromosomal gene locus, termed CLEP tagging (Chromosomal Locus EPitope 
tagging) in vertebrate cells, embryonic stem cells and live mice.  This method allows us 
to purify tagged proteins coded by genes controlled by their native promoter and with the 
use of different tags, facilitating the localization and function of the protein of interest. 
This dissertation comprises five chapters.  Chapter 1 provides an overview of 
our current understanding of the gene expression network with a particular focus on pre-
mRNA splicing machinery and the application of epito e-tagging method on 
characterization of snRNPs.  Chapter 2 contains the materials and methods of CLEP 
tagging technique by inserting a TAP tag or histidine (His) tag into the 3’ terminus of the 
SmD3, SF3b155 and Lsm3 genes in cultured vertebrate cells.  I show that this method 
of purification is robust and sensitive by identification of low-abundance proteins and 
novel proteins involved in splicing that have not been characterized in metazoan cells 
before.  In Chapter 3, I describe that purifying  vivo-assembled pre-mRNA processing 
machines from DT40 cells and HeLa cells expands the catalog of participating factors.  
With a similar CLEP technique, a TAP tag and a polyhistidine tag insertion into the 3’ 
terminus of SART1 gene and U5-220K gene, respectively, in mouse embryonic stem 
cells and generation of mice processing a TAP tagged SART1 gene, are described in 
Chapter 4.  In the last Chapter, I demonstrate that modifying SART1 protein with a TAP 
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tag triggers an autoimmune response in mice which contain a TAP tag at both loci.  
These mice will serve as a valuable tool for the studies of mammalian autoimmune 
diseases.  In summary, the improvement of epitope tagging and purification technique 
extends our understanding of the complex gene expression network. 
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Chapter 2: Gene targeting in cultured vertebrate cells 
2.1 BACKGROUND  
In order to create a biochemical tool in a vertebrate system which circumvents the 
shortcomings of the use of trans-genes, I extended th  use of homologous recombination 
technology in appropriate cell lines capable of efficient homologous recombination 
techniques. 
2.1.1 A vertebrate cell line useful for gene targeting 
The DT40 chicken pre-B cell line is derived from avian leucosis virus (ALV)-
induced bursal lymphoma, expressing IgM on its surface (sIgM).  These cells have 
integrated the 3’ viral long terminal repeat upstream of the c-myc gene, resulting in the 
transcription of c-myc at levels 100-fold higher than normal avian bursal cells (Baba et 
al., 1985).  Importantly, the c-myc gene is deregulated by adjacent retroviral integration 
in these lymphocytes and maintains them in a stem-cll stage (Thompson et al., 1987).  
Deregulation of c-myc gene during B cell development in the Bursa blocks differentiation 
and leads to the expansion of the bursal stem cell population.  Baba et al. and Kim et al. 
further reported that these cell lines possessed distinct c-myc alleles; some contained one 
normal and one deregulated c-myc while others lacked normal c-myc genes, suggesting 
these cells generated a mitotic recombination event among the parental alleles (Baba et 
al., 1985; Kim et al., 1990).  DT40 is also an ideal model for the study of somatic 
diversification mechanisms after immunoglobulin gene rearrangement as DT40 cells 
continue to undergo gene conversion as shown by testing for the presence of absence of 
restriction sites within the light chain variable region (Thompson et al., 1987). 
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 In 1991, Buerstedde t al. reported that DT40 cells exhibited high frequencis of 
targeted integration several orders of magnitude higher than the frequencies reported for 
transfection of mammalian cells (Buerstedde and Taked , 1991).  After transfection 
with a construct containing a neomycin resistance gene (neoR) into the immunoglobulin 
gene locus, the DT40 cells lost their surface IgM expr ssion due to the targeted 
integration.  The high frequency of targeted integration was neither restricted to the gene 
conversion activity within the light chain locus nor restricted to the untranscribed genes, 
as they tested targeted integration into the β-actin locus (unrelated to light chain locus) 
and ovalbumin locus (not transcribed in chicken B cells).  This cell line offers a targeted 
DNA integration frequency of 10% to 90%, depending o  the locus of interest. 
The use of the DT40 cells is increasing in popularity because of the ease with 
which it can be manipulated in suspension tissue culture media, the high rate of 
homologous recombination, a rapid (8-hour) doubling t me, and exceptional conservation 
with mammalian cells of cellular processes.  The high frequency of targeted integration 
is a general feature of DT40 and it has been widely used in gene disruption experiments, 
contributing to our understanding of diverse processes including B cell antigen receptor 
signaling, apoptosis, histone gene function, RNA processing, DNA repair, and cell cycle 
[reviewed in (Winding and Berchtold, 2001)]. 
2.1.2 A human cell line useful for gene targeting 
Only a few reports on successful gene targeting in human cell lines are available.  
Unfortunately, none of them were shown to be more recombinogenic than the others.  In 
2004, Feederle et al. reported a human EBV-negative Burkitt lymphoma B-cell line, 
DG75, capable of efficient homologous recombination similar to that of the DT40 system 
(Feederle et al., 2004).  They generated a homozygous knockout of a cellular gene 
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encoding a protein interacting with a viral origin of replication and showed that genetic 
manipulation of DG75 cells was relatively easy.  This report provided a useful tool for 
studying function through gene targeting in human cells. 
In this chapter, I take an advantage of the efficient homologous recombination in 
the DT40 cell line to insert an epitope-tag in the chromosome locus of a gene by 
homologous targeting.  I employ chicken DT40 pre-B cells to TAP- or (His)8-tag the 
SmD3, SF3b155 or Lsm3 genes in this model vertebrat cell line (Buerstedde and 
Takeda, 1991).  Tagging these ribonucleoprotein components allows us to perform 
proteomic and functional analyses of the splicing machinery in metazoans. 
2.2 MATERIALS AND METHODS  
2.2.1 The design of targeting vector  
The general strategy for the CLEP tagging procedure is shown in Figure 2.1.  To 
create the targeting vector, three DNA regions from the gene of interest were amplified 
by polymerase chain reaction (PCR) from genomic DNA purified from DT40 cells.  The 
AB fragment (Figure 2.1B) is the region of 1 – 4 Kbupstream of the stop codon of the 
gene of interest containing a BamHI or BglII site immediately upstream of the STOP 
codon.  The 5’ end of the AB fragment is generally designed to be contained in an 
intronic sequence.  The CD fragment (Figure 2.1B) is typically the 1 Kb of genomic 
DNA downstream of the STOP codon of the gene of interest, although this may be made 
longer if the sites of cleavage polyadenylation are known to be further downstream that 1 
Kb from the STOP codon.  The EF fragment is the region 2-4 Kb further downstream of 
the CD fragment.  All fragments were PCR amplified (Expand High Fidelity PCR kit, 
Roche Applied Science) from the genomic DNA purified from the DT40 cells and cloned 
in the pGEM-T-Easy (Promega) vector.  All fragments were sequenced to verify that the 
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coding region and splice site signals in AB have ben maintained and to verify the 
identity of the CD and EF fragments.  The AB, CD, and EF fragments for each gene 
were amplified using oligonucleotides as shown in Table 2.1. 
The targeting vector backbone we used is pOSDUPdel (a kind gift of W. Kuziel), 
a positive-negative selection vector, containing a neomycin phosphotransferase gene 
(neo) cassette flanked by loxP sites and a thymidine kiase gene conferring ganciclovir 
resistance.  The restriction enzyme sites used in these constructions are flexible.  The 
AB and CD fragments are cloned into the first polylinker region containing the following 
sites, in order: NotI, PmeI, XbaI, HinDIII, KpnI, HpaI, SalI, BamHI and PacI.  The EF 
fragment is cloned into the second polylinker region containing the following sites in 
order: ClaI, XhoI, PmlI, BclI, and NheI.  For simplicity, NotI and SalI are generally 
used for cloning of the AB fragment and SalI and PacI for the cloning of the CD 
fragment as it eliminates the BamHI site in the polyliner such that a BamHI fragment 
containing the epitope tag can be inserted or replac d as needed.  Alternatively, the 
epitope tag-containing BamHI fragment can be added to the AB fragment in the pGEM-
T-Easy vector.  The cloning strategy should take into account the order in which the 
fragments are inserted into the targeting vector, and ensure that the sites used for cloning 
are absent from the fragments yet to be inserted.  The epitope tag, TAP or (His)8, is 
contained on a BamHI restriction fragment and cloned into the BamHI or BglII site 
incorporated into the AB fragment. 
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Figure 2.1 Strategy for the epitope tagging technolgy in DT40 cells, ES cells and 
live mice.   
(A) Idealized gene structure of a metazoan gene.  Exons are represented by solid 
rectangles, introns by thin lines.  The epitope tag is represented by a grey rectangle.  
(B) Targeting vector fragment containing the sequences required for the introduction of 
the epitope tag, and the regions of homology for the targeting of the gene.  (C) Idealized 
gene sequence with targeting construct inserted.  Locations of oligonucleotides used in 
PCR and RT-PCR (PCR5 and PCR3) are noted by arrows.   
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Table 2.1 Oligonucleotides used for targeting vector construction in DT40 cells 
Targeted gene Oligo sequence 
GgLSM3-A 5’-GCGGCCGCGGTGAGGACAGATCCACGATGCACTGG-3' 
GgLSM3B-HIS  5’-GTCGACGGATCCTTAGTGGTGATGATGATGATGATGATGGG 
 ATCCGCC AACCCTCAGTGGGGGAGCTACAAGCAC-3' 
GgLSM3-C 5’-GTCGACAGCAACCAAGGATTGAACCTTCTTGGAAG-3' 
GgLSM3-D 5’-TTAATTAAGGATCCTAGGCAAGGTATGTCAAGAAATGCCTG-3’ 
GgLSM3-E 5’-CTCGAGGGATCCGGTTTTAGACACGTTCTGTACAATCATC-3' 
GgLSM3-F  5’-GCTAGCGCAACTTCTGGGCAAAAAGGGAAGGCAAATG-3' 
GgSF3b155-A  5’-GCGGCCGCCTTCCAACCCAAACATTCTGTGATTCTC-3' 
GgSF3b155-B-HIS  5’-GTCGACGGATCCTTAGTGGTGATGATGATGATGATGATGGG 
 ATCCTAAGATGTAGTCAAGTTCATAACGAATATAGG-3’ 
GgSF3b155-C  5’-GTCGACTCTTCTTGTTCTGTTGTTTGTGTTTAATGC-3’ 
GgSF3b155-D 5’-TTAATTAAGGATCCAACACTACCAGAATGACGTAACCTTGTG-3’ 
GgSF3b155-E 5’-CTCGAGGGATCCGGGTAGTGTTTCATGTCCATAAGAAAAC-3’ 
GgSF3b155-F 5’-GCTAGCGTACTTTCCAAGACAGTTTAGAGTTTGGCAG-3’ 
Gg SmD3-A 5’-GCGGCCGCAGGCTGTATGCTTGACAGGGCTTTGAG-3’ 
GgSmD3-B  5’-GTCGACAGATCTTCTTCGCTTCTGGAAGATGTTGCCACGACC-3' 
Gg SmD3-C 5’-GTCGACGACCAGTATGCTTTTTTTTATTAGAGG-3’ 
Gg SmD3-D 5’-TTAATTAAGGATCCTCATTCATACATGTATAGACTGATGAC-3’ 
Gg SmD3-E 5’-CTCGAGGGATCCTATAAAGACCCCCTGTGTGCAGACATG-3’ 
Gg SmD3-F  5’-GCTAGCCCTTCTATCCACAGGTGTGATCTTCC-3' 
 
 
2.2.2 DT40 cell culture and targeting vector transfection 
2.2.2.1 Growth condition and media preparation 
DT40 cells were grown in Dulbecco’s modified Eagle media (DMEM) 
supplemented with 5% chicken serum, 5% fetalplex (Gemini Bio-Products), and 
antibiotics (penicillin/streptomycin, 100X, Gibco/invitrogen).  When cultured at 37℃ 
with 8% CO2, the generation time for the wild-type cells is about 8 hours.  
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2.2.2.2 Cryopreservation of cells 
 The cells were grown in 30 mL medium to confluency (~106 cells/mL), followed 
by centrifugation for 5 minutes at 1000 rpm.  The cll pellets were thoroughly 
resuspended in cryopreservation media: 2 mL solution A (16 ml of DMEM with 4 mL of 
fetalplex) and 2 mL solution B (15 ml of DMEM, 6 ml fetalplex and 9 ml of DMSO); 
aliquot 1 mL into each of 4 labeled cryovials.  The cryovials were stored in styroform 
boxes in -80˚C for 2 days and then moved into liquid nitrogen. 
2.2.2.3 Recovery of frozen cultured cells 
The cryovials were thawed in a 37˚C water bath, with frequent shaking.  Thawed 
cells were transferred into 5 mL DMEM media, and centrifuged for 5 minutes at 1000 
rpm.  The pelleted cells were resuspended in 10 ml of DMEM media.  Cells were 
grown in a T25 flask to confluence. 
2.2.3 DNA transfection into DT40 cells 
After the targeting vectors containing the epitope tagging fragment were created, 
the plasmid DNA (20-30 µg) was linearized at a uniqe site (generally NotI or NheI) and 
electroporated into the DT40 cells.  Generally, 107 DT40 cells, in 300 µl of  phosphate 
buffered saline, PBS , (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4)  
were transferred into cuvettes and electroporated with 20 µg linearized targeting 
constructs (BioRad Genepulser II, 700 V, 25µF, 0.4 cm cuvette).  After electroporation, 
the cells were recovered in 15 ml non-selective media for 24 hours, then harvested and 
resuspended into 40 ml of selective media containing 1.5 mg/ml of G418 for neomycin 
selection.  100 µl aliquots were distributed into each well of four 96 well plates.  G418-
resistant cells formed colonies after 10-14 days in selective media.  They were expanded 
into 48 well plates and grown in G418 selection media until confluent.  RT-PCR or 
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western blot analyses were performed to confirm the presence of the epitope-tag insertion 
into the correct chromosomal locus.  
2.2.4 Screening for tagged gene by RT-PCR analysis 
For screening DT40 cells positive for SmD3-TAP, Lsm3-(His)8, SF3b155-(His)8, 
total RNA was isolated (RNAwiz, Ambion) from 105 cells for RT-PCR analysis using 
oligonucleotides as shown in Table 2.2.  RNA was resuspended in 30 µl RNase free-
water and 50ng of RNA was used for one step RT-PCR (One Step RT-PCR kit, Qiagen). 
Table 2.2 Oligonucleotides for RT-PCR analysis in DT40 cells 
Targeted gene Oligo sequence 
Gg LSM3PCR5 5’-ACGCATATGATCAGCATTTAAATATGATTC-3' 
Gg LSM3PCR3  5’-AGCCTGAAACCTTCCAAGAAGGTTCAATCC-3’ 
GgSF3b155PCR5  5’-TTGCAGTATTGTTTGCAGGGTTTGTTTCAC-3’ 
GgSF3b155PCR3  5’-TTA TGTGAAGAACAGCTGTGCATTAAACAC-3’ 
GgSmD3PCR5 5’-CGAGGAAAAGCAGCTATTCTCAAAGCTCAG-3’ 
GgSmD3PCR3 5’GACAGAAGTTACCAACATATATGTAGAC-3’ 
 
 
2.2.5 Screening for tagged gene by western blot analysis 
105 cells were lysed by addition of 200 µl LDS-PAGE loading buffer [4X sample 
buffer (pH 8.5): 106 mM Tris-HCl, 141 mM Tris base, 2% LDS 10% glycerol, 0.51 mM 
EDTA, 0.22 mM SERVA Blue G250, 0.175 mM phenol red] and homogenized samples 
(20 µl) were electrophoresed through 10% SDS-PAGE gels and transferred to 
nitrocellulose membrane.  Membranes were blocked for 1 hour in PBST (PBS + 0.2% 
Tween 20) containing 5% dry milk solution.  Membranes were then incubated with 
Peroxidase-antiperoxidase (PAP) antibody (Sigma) (1:1000 dilution) for 1 hour to detect 
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TAP tagged proteins.  After washing membranes extensiv ly with PBST, the signal was 
detected by enhanced chemiluminescence (Perkin Elmer). 
2.2.6 Extract preparation 
Six liters of SmD3-TAP DT40 cells were grown in Dulbecco’s modified Eagle 
media supplemented with 5% chicken serum and 2.5% Fetalplex to a density of 7.5×105 
cells/ml for TAP purification.  Cells were harvested by centrifugation (400 x g for 5 
minutes), washed twice with ice cold PBS, allowed to swell in 10 ml of TM buffer [10 
mM Tris-HCl, (pH 7.5), 3 mM MgCl2] with 0.2 mM PMSF, 1 µg/ml leupeptin, and 1 
µg/ml pepstatin for 10 minutes on ice, and lysed with 25 strokes of a Dounce 
homogenizer at 4˚C.  The nuclei were pelleted, washed twice with 10 ml of TM buffer 
containing 0.1% NP40, resuspended in 5 ml of low salt buffer (30 mM Tris-HCl, 125 
mM KCl, 5 mM MgCl2, 0.5% Triton-X100, 0.15mM spermine, 0.05mM spermidine, and 
0.2 mM PMSF), and sonicated at the maximum output, twice for 20 seconds on ice with 
1 minute in ice between sonications.  The sonicated mixture was centrifuged at 5000 
rpm for 10 minutes and the supernatant, the nuclear fraction, was used for TAP 
purification.   
2.2.7 TAP purification procedure 
TAP-tagged nuclear protein material for SmD3-TAP DT40 cells was affinity 
purified by the TAP procedure (Puig et al., 2001).  The nuclear fraction was incubated 
with 400 µl of IgG sepharose beads for 2 hours at 4˚C in buffer IPP150 (10 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 0.1% NP40).  The tagged protein and associated material were 
recovered from extracts by IgG affinity selection.  After washing with 100 column 
volumes of IPP150, the beads were suspended in TEV cleavage buffer (IPP150 
containing 1 mM DTT).  TEV protease (2 µl for 400 µl bead volume) was added to 
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release the bound material at 16˚C for 2 hours.  The eluate was then incubated with 200 
µl calmodulin-coated beads in IPP150 calmodulin binding buffer (10 mM Tris-HCl pH 
8.0, 150 mM NaCl, 0.1% NP40, 10 mM 2-mercaptoethanol, 1 mM magnesium acetate, 1 
mM imidazole, 2 mM CaCl2) and rotated for 1 hour at 4˚C.  The calmodulin-coated 
beads were washed with 100 column volumes of IPP150 calmodulin binding buffer, and 
the bound material was released with IPP150 calmodulin elution buffer (10 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 0.1% NP40, 10 mM 2-mercaptoethanol, 1 mM magnesium 
acetate, 1 mM imidazole, 4 mM EGTA).  Five elution fractions of 200 µl each (1 bead 
volume) were collected.  RNA and protein were separated by phenol/chloroform 
extraction.  RNA samples from aqueous phase were precipitated by addition of 0.3 M 
NaOAc, pH 5.3 and followed by addition of 2.5 sample volumes of 100 % ice-cold 
ethanol, assayed on 7% polyacrylamide gel (19:1), and visualized by ethidium bromide or 
silver stain.  Protein samples were precipitated by 5 sample volumes of ice-cold acetone 
from the organic phase, assayed on 10% SDS-PAGE gel, and visualized by staining with 
silver or Coomassie blue G-250.  
2.2.8 Mass spectrometry analysis 
SDS-PAGE separated affinity purified polypeptides were excised from the gel 
analyzed by mass spectrometry (LS/MS/MS) as previously described (Davis and Lee, 
1998; Moore et al., 2000).  Fragmented ion mass spectra were screened and searched 
against the NCBI non-redundant database using the Sequest matching program.  The 
Qscore scoring procedure was used to measure the quality of the results for protein 
identification obtained from the peptide fragment matching of the MS/MS data using the 
Sequest database program (Moore et al., 2002).  Scoring system is based on the 
estimation of the probability that protein identification was by chance.  Based on the 
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number of identified peptides from the protein, theotal number of identified peptides, 
and the percentage of distinct tryptic peptides from the database covered in the identified 
proteins, the Qscore is assigned to each identified proteins.  This scoring system allows 
us to eliminate contaminants from the Sequest protein id ntifications. Consequently, each 
individual spectral fragment is validated manually to ensure that each peak matches the 
molecular weight of proteins on the gels. 
2.3 RESULTS 
2.3.1 DT40 cells carrying CLEP tags 
I employed the chromosomal locus epitope tagging procedure in a model 
vertebrate system, the DT40 chicken pre-B cell line.  I chose three target genes in DT40: 
the SmD3, SF3b155 and Lsm3 genes encoding polypeptides participating in pre-mRNA 
splicing and/or RNA turnover.  The design of the targeting vectors was performed as 
described above.  After construction and clone validation, the targeting vector was 
linearized at an appropriate site upstream of the AB fragment (usually NotI) or 
downstream of the EF fragment and electroporated into DT40 cells.  The cell colonies 
that survived in the presence of G418 selection media were chosen and expanded.  The 
presence of correctly targeted cells was tested by PCR using one oligonucleotide primer 
designed outside the targeting region (PCR5 in Figure 2.1) and one oligonucleotide 
primer designed inside the targeting vector (PCR3 in Figure 2.1).  Lsm3-(His)8 was 
positively identified in 19/30 colonies (Figure 2.2), SF3b155-(His)8 was identified in 
12/30 colonies (Figure 2.2) and SmD3-TAP was recovered in 2/20 colonies (Figure 2.3A 
and 2.3B).  I note that the smaller size of the (His)8 tag is a likely reason they were more 
efficiently recovered than TAP-tagged constructs (10% of positives in the TAP-tagged 
construct vs. 63% and 40% for HIS-tagged constructs). However, I did not try to insert 
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different tags into same chromosomal locus.  One-step purification using Ni-NTA 
affinity chromatography to purify SF3b155-(His)8 and Lsm3-(His)8 associated 
components was not efficient or pure from chicken clls so I did not proceed with further 
experiments with these two tagged cell lines. 
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Figure 2.2 Targeted insertion of (His)8 tags into DT40 genes.  
RT-PCR analysis of SF3b155-(His)8 and Lsm3-(His)8 targeting construct insertion into 
the respective DT40 genes.  Lower band represents the wild-type allele and upper band 
represents the targeted allele.   
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Figure 2.3 Targeted and functional insertion of TAP tag into DT40 genes. 
(A) RT-PCR analysis of SmD3-TAP targeted clones.  Lower band represents the wild-
type allele and upper band represents the targeted all le.  (B) Western blot analysis of 
SmD3-TAP clones.  SmD3-TAP polypeptide is noted. 
 
 
 
2.3.2 Identification of SmD3-associated polypeptides 
To demonstrate functional association of the tagged material with its native 
cellular machinery, 6 liters of SmD3-TAP DT40 cells were grown to a density of  
7.5x105 cells/ml.  Cells were harvested and nuclei were fractionated and disrupted by 
sonication.  SmD3-TAP-associated material was purified by the TAP procedure (Puig et 
al., 2001) and associated polypeptides were separated by SDS-PAGE (Figure 2.4) and 
analyzed by mass spectrometry peptide analysis (Davis nd Lee, 1998).  SmD3-
associated polypeptides from selected bands are shown in Table 2.3.  The identified 
polypeptides correlate to most of the known SmD3-associated spliceosomal snRNP 
proteins (Jurica and Moore, 2003) demonstrating that e SmD3-TAP polypeptide is 
SmD3-TAP 
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being faithfully incorporated into functional complexes and includes factors shown to be 
only loosely associated (Will et al., 2002)(e.g. SR140, SAP45 and SAP30).  Indeed even 
very low-abundance U11/U12 snRNPs (U11/U12-65K and U11/U12-48K) were 
identified in the salt-stable snRNP fractions demonstrating the sensitivity of the 
procedure. 
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Figure 2.4 Functional incorporation of SmD3-TAP into splicing snRNPs.  
Untagged DT40 and tagged SmD3-TAP cell nuclei were subjected to TAP purification 
procedures (Puig et al., 2001) and affinity-purified polypeptides resolved by SDS-PAGE.  
TEV elution and calmodulin elution profiles are shown for each.  An asterisk marks the 
location of the TEV protease.  
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Table 2.3 SmD3-associated polypeptides 
Identified protein ENSEMBL name snRNP association 
U1-70K ENSG00000104852* U1 
U1C ENSGALG00000002773 U1 
U1A ENSGALG00000008729 U1 
SF3b155 ENSGALG00000008038 U2 
SF3b145 ENSG00000087365* U2 
SF3b130 ENSGALG00000002531 U2 
SF3b125 ENSGALG00000000581 U2 
SF3a120 ENSGALG00000007937 U2 
SF3a60 ENSGALG00000001540 U2 
DDX15/Prp43 ENSGALG00000014395 U2 
SR140 ENSGALG00000002612 U2 
SPF45 ENSGALG00000006332 U2 
SPF30 ENSGALG00000008561 U2 
U2B’’ ENSGALG00000008729 U2 
U2A’ ENSGALG00000007170 U2 
SF3b14 ENSGALG00000016501 U2 
U5-220K ENSGALG00000002943 U5, U4/U6•U5 
U5-200K ENSGALG00000015465 U5, U4/U6•U5 
U5-116K ENSGALG00000000988 U5, U4/U6•U5 
U5-110K ENSG00000175467* U5, U4/U6•U5 
U5-102K ENSGALG00000006001 U5, U4/U6•U5 
U5-100K ENSG00000174243* U5, U4/U6•U5 
U5-40K ENSGALG00000000615 U5, U4/U6•U5 
U5-15.5K ENSGALG00000017396 U5, U4/U6•U5 
U4/U6-90K ENSGALG00000000465 U4/U6, U4/U6•U5 
U4/U6-61K ENSG00000105618* U4/U6, U4/U6•U5 
U4/U6-60K ENSGALG00000008857 U4/U6, U4/U6•U5 
U4/U6-20K ENSGALG00000004874 U4/U6, U4/U6•U5 
U4/U6-15K ENSGALG00000011931 U4/U6, U4/U6•U5 
U4/U6•U5-65K ENSG00000168883* U4/U6•U5 
SmB/SmB’ ENSGALG00000007250 U1, U2, U4/U6, U5 
SmD3 ENSGALG00000006596 U1, U2, U4/U6, U5 
SmD2 ENSG00000125743* U1, U2, U4/U6, U5 
SmD1 ENSGALG00000011842 U1, U2, U4/U6, U5 
SmE ENSGALG00000000137 U1, U2, U4/U6, U5 
SmF ENSGALG00000011409 U1, U2, U4/U6, U5 
SmG ENSG00000143977* U1, U2, U4/U6, U5 
SART3 ENSGALG00000004887 U6, U4/U6 
Lsm2 ENSG00000111987* U6, U4/U6, U4/U6•U5 
Lsm6 ENSGALG00000009985 U6, U4/U6, U4/U6•U5 
Lsm8 ENSGALG00000009110 U6, U4/U6, U4/U6•U5 
U11/U12-65K ENSGALG00000005162 U11/U12 
U11/U12-48K ENSGALG00000013005 U11/U12 
Prp38 ENSGALG00000010627 Yeast U4/U6•U5** 
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Table 2.3 (Continued) 
Identified protein ENSEMBL name snRNP association 
Prp39 ENSGALG00000012468 Yeast U1** 
 
* Not annotated for Gallus gallus.  Identification was based on database calls to   
orthologues from other species. 
** Not previously shown to be snRNP-associated in metazoans 
 
 
2.3.3 Previously uncharacterized metazoan snRNP polypeptides associated with 
SmD3 in chicken cells 
The yeast genes PRP38 and PRP39 encode polypeptides that are associated with 
the yeast U4/U6•U5 and U1 snRNPs, respectively (Gottschalk et al., 1998; Stevens and 
Abelson, 1999).  These two polypeptides have never b en shown to be stable 
components of metazoan snRNPs when purified using a monoclonal antibody. However, 
they were identified in our purification, confirming the robustness of the CLEP tagging 
purification procedure.  Sequence alignments of the vertebrate homologues of the yeast 
Prp38p and Prp39p are presented in Figures 2.5 and 2.6, respectively.  
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Figure 2.5 Sequence alignments of polypeptide homologues of yeast Prp38p.  
Sequences from Human (HsPrp38), chicken (GgPrp38), and worm (CePrp38) were 
aligned with yeast Prp38p polypeptides.  Identical amino acid residues are highlighted 
with white text on a black block.  Similar amino acid residues are highlighted with black 
text on a gray block. 
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Figure 2.6 Sequence alignments of polypeptide homologues of yeast Prp39p.  
Sequences from Human (HsPrp38), chicken (GgPrp39), and worm (CePrp39) were 
aligned with yeast Prp38p polypeptides.  Identical amino acid residues are highlighted 
with white text on a black block.  Similar amino acid residues are highlighted with black 
text on a gray block. 
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2.4 DISCUSSION  
I have demonstrated the feasibility and promise of incorporating epitope tags into 
the chromosomal loci of essential genes in cultured vertebrate cells.  I also have shown 
that the procedure is robust and highly sensitive, as loosely associated factors and 
extremely low-abundance material such as the U11/U12 snRNP proteins, were purified 
and identified by mass spectrometry.  Indeed a comparison between conventional 
antibody chromatography and the use of the CLEP tag shows a much greater number of 
polypeptides identified by mass spectrometry using the CLEP tag. 
With tissue culture cells, once a tagged cell line has been established using CLEP, 
an unlimited supply of cells can be grown for experim ntation for which precious and 
expensive antibodies were previously required.  Purification of protein complexes 
controlled under its native promoter enhances the validity of conclusions made regarding 
epitope-tagged proteins versus the use of a trans-ge e.  Furthermore, the use of different 
epitope tags on multiple genes will not only allow additional flexibility and 
experimentation, such as co-immunoprecipitation analysis, but also offer a useful method 
for the separation of subsets of complexes in which a polypeptide of interest exists in 
multiple complexes with mutually exclusive binding partners.  Along with recent and 
future progress in genome sequencing, these experiments will be easily applicable to 
other metazoan organisms for which extensive genomic sequencing has been performed, 
and for which cells possessing efficient homologous recombination are available.  
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Chapter 3: Proteomic analysis of the endogenous pre-mRNA processing 
machinery 
3.1BACKGROUND  
Pre-mRNA splicing is a fundamental step in eukaryotic gene expression before 
the mature mRNA is exported from the nucleus to the cytoplasm where it is translated 
into protein.  The machinery that splices pre-mRNA is called the spliceosome which is 
comprised of hundreds of proteins and five small nuclear RNAs (U1, U2, U4, U5, and 
U6) assembled into small nuclear ribonucleoproteins (snRNPs).  In addition to the 
snRNP specific proteins, a large number of spliceosome-associated proteins were 
identified through biochemical or genetic studies.  These proteins include DEAD-box 
helicase family members, RNA binding proteins, SR proteins, and spliceosome 
associated proteins, which are important for regulating the many temporally and spatially 
important RNA and protein rearrangements during the splicing reaction (Staley and 
Guthrie, 1998). 
In an alternative systematic approach to the traditional characterization of the 
individual snRNP, several groups have purified and characterized spliceosomes using a 
large-scale proteomic analysis (Neubauer et al., 1998; Rappsilber et al., 2002; Zhou et al., 
2002).  These purifications involved the assembly of spliceosomes from salt-extracted 
HeLa nuclei onto synthetic single-intron pre-mRNAs in vitro to purify spliceosomes from 
a mixture of all stages of assembly.  Zhou et al. assembled spliceosome on AdML-M3 
(adenovirus major late) pre-mRNA containing three hairpins that bound to the MS2-MBP 
fusion protein used for affinity chromatography.  Neubauer et al. and Rappsilber et al. 
used biotin-labeled AdML and β-globin transcripts as substrates for the spliceosome 
assembly followed by streptavidin bead affinity selection.  Combined with the 
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improvements in mass spectrometric methods and expanding gene databases, these three 
comprehensive proteomic analyses of the human spliceosome revealed a remarkably 
large number of polypeptides associated with splicing omplexes.  
Nevertheless, native pre-mRNAs contain multiple, often extremely large introns; 
the in vitro pre-mRNA splicing reactions were carried out using synthetic pre-mRNA 
fragments containing a single, efficiently spliced intron of a size compatible with 
acrylamide gel electrophoresis analysis.  Although the core pre-mRNA processing 
machinery will likely be very similar between different transcripts as well as for the 
multiple introns contained within a single transcript, the bulk pre-mRNA processing 
machinery purified from its native context is likely to contain a more comprehensive 
sample of the polypeptides required for or participating in the splicing of pre-mRNA in 
vertebrate cells.  In addition, the spliceosomes purified from in vitro reactions were 
assembled on pre-mRNAs derived from either the adenovirus major late or β-globin loci.  
Thus, it is likely that there exist a number of factors that are required for or participate in 
pre-mRNA processing in vivo, yet are not present in previously purified splicing 
complexes because they are specific to one or more of the thousands of other pre-mRNAs 
present in metazoan cells.  Finally, the pathway by which pre-mRNA processing 
complexes are assembled in vitro using salt-extracted nuclear fractions most likely 
bypasses many interactions relevant to this process in vivo.  Thus, spliceosomes purified 
following in vivo assembly are expected to contain additional components that reflect the 
native pathway, but are not required to effect model intron removal in vitro.   
Consistent with this view, other investigators have shown that endogenous pre-
mRNA is processed in extremely large ribonucleoprotein particles, called 
supraspliceosomes (Azubel et al., 2004; Muller et al., 1998; Sperling et al., 1985) or 
polyspliceosomes (Wassarman and Steitz, 1993), which sediment at ~200S in sucrose 
 49 
gradients.  Biochemical and structural analyses of these complexes have demonstrated 
the presence of RNA Pol II transcripts and the pre-mRNA splicing machinery as well as 
functional interactions that mirror those in active splicing complexes assembled in vitro 
(Wassarman and Steitz, 1993).  The higher-order particles formed in vivo partly reflect 
the presence of multiple introns, an average of eight per pre-mRNA (Lander et al., 2001) 
with some transcripts possessing as many as 147 introns [Nebulin (Sakharkar et al., 
2004)], that need to be faithfully removed prior to nuclear export. 
With the goal of expanding our understanding of pre-mRNA splicing as it occurs 
in intact cells, I have purified the endogenous pre-mRNA processing machines from 
chicken DT40 pre-B cells on a preparative scale andhave defined their RNA and 
polypeptide compositions in this chapter.  The results from chicken DT40 cells are 
compared with that from HeLa polyspliceosome purified by conventional means, using 
Y12 antibodies against Sm proteins (a gift of Joan Steitz).  I chose the chicken DT40 
system to compare to the HeLa system for a number of r asons.  First, I have shown that 
this rapidly growing cell type, which possesses high rate of homologous recombination, 
allows for efficient epitope-tagging of genes.  The evolutionary distance between human 
and chicken will allow me to assess the evolutionary conservation of the machinery as 
well as validating novel co-purifying factors.  I show that these pre-mRNA processing 
complexes contain spliced and unspliced mRNAs, all five spliceosomal snRNAs and 
polypeptides involved in all aspects of pre-mRNA processing from transcription to 
nuclear export.  
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3.2 MATERIALS AND METHODS  
3.2.1 Purification of human supraspliceosome from HeLa cells 
Ten liters of HeLa cells (purchased from the National Cell Culture Center) were 
processed essentially as previously described (Sperling et al., 1985).  Briefly, cells were 
washed in PBS and disrupted by mechanical breakage in a glass dounce (20 strokes, 
pestle “B”) in a hypotonic solution (30 mM Tris-HCl pH 7.5, 10 mM KCl, 5 mM MgCl2, 
10 mM 2-mercaptoethanol) at 4˚C.  Nuclei were pellet d at 1000 x g at 4˚C for 5 
minutes through the hypotonic buffer containing 25% glycerol.  The nuclei were washed 
three times in the hypotonic buffer containing 0.5% Triton X-100 and once with 
detergent-free hypotonic buffer.  Nuclei were resuspended in a low-salt buffer (LS+; 10 
mM Tris-HCl pH 7.5, 100 mM KCl, 2 mM MgCl2, 10 mM 2-mercaptoethanol, 0.15 mM 
spermine, 0.05 mM spermidine) and sonicated twice for 20 seconds at the maximum 
microtip setting.  The resulting nuclear debris was pelleted at 14,000 RPM for 10 
seconds, and the supernatant was layered onto a 15-45% glycerol gradient (11 ml 
Beckman SW41, 125 mM KCl, 20 mM HEPES, 1.5 mM MgCl2, 10% NP40, 10 mM 2-
mercaptoethanol, 0.2 mM PMSF) made isotonic to LS- buffer (LS buffer without 
polyamines) and sedimented at 40,000 RPM for 90 minutes.  Fractions (420 µl) were 
collected from the top.  Protein and nucleic acid were separated by phenol/chloroform 
extraction and precipitation with acetone (protein) or ethanol (nucleic acid) (Stevens, 
2000).  Fractions corresponding to the supraspliceosomes were pooled from six velocity 
gradients run in a parallel fashion, diluted to ~ 8% glycerol with LS- buffer and incubated 
with 20 mg Y12 antibody which had been covalently atached to 1 g CnBr-sepharose (GE 
Biosciences) according to the manufacturer’s instructions.  After incubation with 
rotation for two hours at 4˚C, the sepharose matrix was washed with 200 ml LS- buffer 
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by gravity flow in a column and supraspliceosome materi l was eluted with 0.2 M 
glycine.  Protein and nucleic acids were separated by phenol/chloroform extraction as 
described in section 2.2.7.   
3.2.2 Purification of chicken supraspliceosome from DT40 cells 
Six liters of SmD3-TAP DT40 cells (Chen et al., 2006) were grown in Dulbecco’s 
modified Eagle media supplemented with 5% chicken serum and 2.5% Fetalplex (Gemini 
Bio-Products) to a density of 7.5×105 cells/ml for TAP purification.  Cells were 
harvested by centrifugation (1000 x g for 5 minutes) and washed twice with ice cold PBS.  
Nuclear extracts preparation and TAP-tagged protein material for SmD3-TAP DT40 cells 
was affinity purified by the TAP procedure (Puig et al., 2001) as described in section 
2.2.6 and 2.2.7.  The TEV eluate was layered onto glycerol gradients and fractionated; 
fractions corresponding to the supraspliceosomes were phenol/chloroform extracted for 
proteins and nucleic acids analyses.   
3.2.3 Mass spectrometry analysis 
Pooled supraspliceosome protein fractions were separated by polyacrylamide gel 
electrophoresis and stained with Coomassie Blue G-250.  Discrete gel slices were 
dissected from the top of the gel lane to the bottom and all regions were subjected to 
trypsin digestion.  Mass spectrometry and database searching was performed as 
previously described in section 2.2.8. 
3.2.4 Immunopurification of ZFR-associated components 
3.2.4.1 Immunoprecipitation 
Polyclonal antisera directed against the carboxyl-terminal 15 amino acids of 
KIAA0332 and NP_035897 (NCBI accession numbers) were p oduced by Genemed 
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Synthesis and the IgG fraction was partially purified by ammonium sulfate precipitation 
at 50% saturation.  Antiserum or non-immune serum was incubated for one hour at 4˚C 
with the samples of interest prior to addition of 50 µl Protein-A agarose beads.  This 
mixture was incubated one further hour with rotation at 4˚C prior to washing with 4 x 15 
ml IPP150.  Proteins and nucleic acids were released from the matrix by incubation in 
IPP150 at 100˚C for 5 minutes.  The supernatant was collected and phenol/chloroform 
extracted as described above to harvest, separate and precipitate the nucleic acids and 
proteins. 
3.2.4.2 Northern blot analysis 
Nucleic acids were transferred to Brightstar membranes (Ambion) and hybridized 
with snRNA probes consisting of antisense chicken snRNAs transcribed with α32P-GTP 
using T7 RNA polymerase (U5) or SP6 RNA polymerase (U1, U2, U4, U6 snRNAs) 
from plasmids containing cDNA versions of the chicken snRNAs.   
3.2.4.3Western blot analysis 
To determine if ZFR co-migrated with 200S particle in glycerol gradients, HeLa 
nuclear extracts were subjected to glycerol gradient s dimentation and resolved in 10% 
polyacrylamide gels (Graham et al., 2005), transferred to nitrocellulose membranes 
(Biorad) and blotted with  anti-ZFR antiserum (1:1000 dilution).  To determine if ZFR 
is specifically associated with spliceosomal proteins, hPrp43 antiserum was used to detect 
the presence of Prp43 (1:1000 dilution) (a gift of Cindy Will and Reinhard Lührmann).  
Anti-SR140 antiserum was used as a positive control (1:1000 dilution).  The secondary 
antibody used was horseradish peroxidase-conjugated goat anti-rabbit IgG (Rockland; 
1:10,000 dilution) and the signal was detected by enhanced chemiluminescence (Perkin 
Elmer). 
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3.3 RESULTS 
3.3.1 Compositional analysis of the chicken supraspliceosome 
Using the CLEP tagging procedure as described in Chapter 2, I tagged the SmD3 
polypeptide in chicken DT40 cells with the TAP tag t its native genomic locus and 
purified the endogenous chicken pre-mRNA processing complexes from these cells. 
 These cells grow rapidly in suspension with an 8 hour doubling time, making 
them ideal for biochemical studies of this sort.  For each experiment, six liters of SmD3-
TAP-DT40 cells were harvested and the nuclear fraction was processed as described in 
2.2.6 and 2.2.7.  Affinity chromatography was performed according to the TAP 
procedure with the TEV protease digestion proceeding at 16˚C for 2 hours.  The TEV 
eluate was sedimented through a glycerol gradient and the material corresponding to the 
supraspliceosomes, in the 200S region, was isolated.  Associated proteins and nucleic 
acids are shown in Figure 3.1A and 3.1B, respectively.  In Figure 3.2A and 3.2B, the 
proteins and RNA resulting from an identical affinity purification procedure performed 
using extracts from untagged DT40 cells are shown.  The absence of proteins and 
snRNAs indicates that the purification is specific and the proteins identified by mass 
spectrometry are likely to be bona fide supraspliceosome components.  Additional 
confidence is provided in that there is size-selection of these massive complexes as well 
as affinity chromatography. 
3.3.1.1 RNA content of the supraspliceosome 
RNAs corresponding to the supraspliceosome fractions from chicken cells are 
shown in Figure 3.1A.  Identities of the RNAs were confirmed by northern blotting 
(data not shown).  The presence of all five of the spliceosomal snRNAs in this material 
indicates that it contains a mixture of pre-mRNA splicing complexes in varying stages of 
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the splicing reaction as U4 snRNA has been shown to dissociate from the spliceosome 
before the first catalytic step invitro reactions.  Alternatively, it may be interpreted as a 
functional difference between the in vitro and in vivo nature of this analysis as compared 
to previous analyses and that the U4 snRNA is not removed, but only destabilized and 
maintained locally.  The presence of all 5 snRNAs in roughly equivalent amounts also 
lends experimental evidence to the participation of the penta-snRNP in these functional 
complexes. 
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Figure 3.1 Chicken supraspliceosome-associated polypeptides and snRNAs. 
Fractions corresponding to the CLEP-tag purified, glycerol gradient-sedimented chicken 
supraspliceosomes were separated into protein (A) and RNA (B) fractions and 
electrophoresed through SDS-PAGE (A) or urea-PAGE (B) gels and stained with 
coomassie blue (protein) or ethidium bromide (RNA).  The identities of the snRNAs are 
indicated on the right of panel B.  The entire gel lane from (A) was dissected and each 
gel slice was subjected to mass spectrometry protein identification.  The proteins 
identified are reported under the Gg PS column in Tables 3.1-3.5, and 3.7. 
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Figure 3.2 Mock-purified chicken supraspliceosomes. 
(A) Proteins from a mock purification in which untagged DT40 extracts were subjected 
to the TAP purification procedure and the resulting> 200S material subjected to glycerol 
gradient sedimentation and stained with coomassie blu  G-250.  Note the presence of 
small amounts of residual TEV protease frequently seen distributed throughout the 
gradients.  (B) Ethidium bromide-stained nucleic acids from the fractions. 
 
 
 
3.3.1.2 Mass spectrometry analysis of supraspliceosome-associated polypeptides 
Polyacrylamide gel material from the entire chicken supraspliceosome fraction 
lane was dissected and analyzed by tandem mass spectrom try (Davis and Lee, 1998; 
Moore et al., 2000; Moore et al., 2002).  A wide variety of polypeptides were identified.  
We detected very little background contamination of factors unrelated to gene expression.  
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Remarkably, we detected 222 distinct polypeptides in the chicken supraspliceosomes 
(Table 3.1-3.5, and 3.7).  
The polypeptides identified by mass spectrometry were validated by analyzing the 
numbers of peptides identified and percent-coverage for each protein (Appendix A). 
Although there is a distribution of coverage for the identified proteins, we note that some 
snRNP-associated proteins had less than 10% coverage.  Differences in coverage may 
reflect differences in abundance, differences in the size spectrum of trypsin fragments or 
peculiarities in the mass spectrometry detection of a particular peptide.  The low-
coverage of some of the novel polypeptides that mayre sonably be implied to function in 
pre-mRNA processing (i.e. contain RNA biding motifs) may reflect their association with 
a smaller subset of pre-mRNA than a general RNA binding protein such as an hnRNP.  
In the case of one novel factor, ZFR, the percent-coverage was low, 3.4% for chicken, but 
its association with the splicing machinery was verified independently in section 3.3.5. 
In Tables 3.1-3.5, we categorize the identified poly eptides according to function.  
Polypeptides identified from the chicken supraspliceosome are briefly described (see text 
below).   
Known snRNP-associated polypeptides  
By mass spectrometry, we identified nearly all of the known pre-mRNA splicing 
snRNP-associated polypeptides (Table 3.1).  Of the snRNP-associated proteins not 
present in the mass spectrometry results, their inabil ty to be detected correlates with the 
presence of an extramolar hnRNP protein of a similar molecular weight.  The CLEP 
tagging procedure was sensitive enough to detect the presence of two minor AT-AC 
spliceosome components, the U11/U12-65K and U11/U12-48K polypeptides (Will et al., 
2004) in the chicken fractions.  The ability to detect all of the Sm proteins, but not all of 
the Lsm proteins may reflect the difficulty in detecting all of these proteins in splicing 
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complexes as shown previously (Gottschalk et al., 1999; Stevens and Abelson, 1999), the 
five-fold abundance differences of the two classes of proteins or perhaps due to the Lsm 
proteins leaving the spliceosome during the process of pre-mRNA splicing (Chan et al., 
2003). 
snRNP biogenesis factors 
 Previous spliceosome purifications did not yield poly eptides known to be 
involved in snRNP biogenesis.  We note in Table 3.1 that there are three present in the 
chicken supraspliceosomes (SIP1, SMNrp30 and Coilin).  These are factors which are 
involved in the de novo assembly of snRNPs and are contained in Cajal bodies (CBs), a 
site of enriched pre-mRNA splicing factors (Gall et al., 1999).  We hypothesize that we 
may be purifying a small subset of snRNPs in the process of being re-targeted to the CBs.   
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Table 3.1 Comparisons of snRNPs and snRNP biogenesis factors between 
supraspliceosomes purified from human or chicken cells with those purified from 
three in vitro assembled spliceosome experiments. 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
U1 snRNP 
ENSG00000104852 SNRP70 U1-70K • • • • • 
ENSG00000077312 SNRPA U1A •   • • • 
ENSG00000124562 SNRPC U1-C       • • 
                
U2 snRNP 
ENSGALG00000008038 SF3B1 SF3b155 • •   • • 
ENSG00000087365 SF3B2 SF3b145 • • • • • 
ENSGALG00000002531 SF3B3 SF3b130 • • • • • 
ENSGALG00000000581 DDX42 SF3b125 • •       
ENSGALG00000007937 SF3A1 SF3a120 • •   • • 
ENSGALG00000021679 SF3A2 SF3a66 • • • • • 
ENSGALG00000001540 SF3A3 SF3a60 • • • • • 
ENSGALG00000013352 SF3B4 SF3b49 •   • • • 
ENSGALG00000008729 SNRPB2 U2B" • • • • • 
ENSGALG00000007170 SNRPA1 U2A' • • • • • 
ENSGALG00000016501 - SF3b14 •     •   
ENSGALG00000020000 SF3B5 SF3b10 •     •   
                
U2-snRNP associated 
ENSGALG00000014395 DHX15 PRP43/DDX15 • •   • • 
ENSGALG00000002612 - SR140 • •   • • 
ENSGALG00000006332 RBM17 SPF45 •   • • • 
ENSGALG00000008561 SMNDC1 SPF30 •   • • • 
ENSGALG00000003824 CHERP CHERP •   • •   
                
U5, U4/U6 & U4/U6•U5 snRNP 
ENSGALG00000002943 PRPF8 U5-220K • •   • • 
ENSGALG00000003477 ASCC3L1 U5-200K • •   • • 
ENSGALG00000000988 EFTUD2 U5-116K • •   • • 
ENSG00000175467 SART1 U4/U5•U5-110K • •   • • 
ENSGALG00000006001 C20ORF14 U5-102K • •   • • 
ENSG00000174243  DDX23 U5-100K • • • • • 
ENSGALG00000000465 PRPF3 U4/U6-90K • • • • • 
ENSG00000168883   USP39 U4/U6•U5-65K • •   • • 
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Table 3.1 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
ENSG00000105618 PRPF31 U4/U6•U5-61K • •   • • 
ENSGALG00000008857 PRPF4 U4/U6-60K • • • • • 
ENSGALG00000004874 PPIH USA-CYP •       • 
ENSGALG00000000615 WDR57 U5-40K • • •     
ENSGALG00000011931 NHP2L1 U4/U6•U5-15.5k •     • • 
ENSGALG00000017396 TXNL4A U5-15K •       • 
                
AT/AC 
ENSGALG00000005162 RNPC3 U11/U12-65K •         
ENSGALG00000013005 C6ORF151 U11/U12-48K •         
                
Sm/LSM 
ENSGALG00000007250 SNRPB SmB/B' • • • • • 
ENSGALG00000011842 SNRPD1 SmD1 • •   • • 
ENSG00000125743 SNRPD2 SmD2 • •   • • 
ENSGALG00000006596 SNRPD3 SmD3 • •   • • 
ENSGALG00000000137 SNRPE SmE • •   • • 
ENSGALG00000011409 SNRPF SmF • •   • • 
ENSG00000143977 SNRPG SmG • •   • • 
ENSG00000111987 LSM2 LSM2 •     • • 
ENSG00000170860 LSM3 LSM3       • • 
ENSGALG00000003385 LSM4 LSM4 •     • • 
ENSG00000106355 LSM5 LSM5           
ENSGALG00000009985 LSM6 LSM6 • •   • • 
ENSG00000130332 LSM7 LSM7       • • 
ENSGALP00000014820 LSM8 LSM8 • •   •   
                
snRNP biogenesis 
ENSGALG00000010154 SIP1 SIP1  •         
ENSG00000119953 SMNDC1 SMNrp30 •         
ENSGALG00000003158 COIL Coilin •         
 
a Data available at http://www.ensembl.org; b HUGO Gene Nomenclature Committee designation, a dash 
represents a polypeptide which has not yet been assigned a systematic name; c Common name; d Gallus 
gallus supraspliceosome; e Homo sapiens (HeLa) supraspliceosome; f Neubauer et al. spliceosome data 
(Neubauer et al., 1998); g Rappsilber et al. spliceosome data (Rappsilber et al., 2002); h Zhou et al. 
spliceosome data (Zhou et al., 2002). f,g,h were compiled from Jurica and Moore (Jurica and Moore, 2003). 
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Known spliceosome associated proteins (SAPs) 
In Table 3.2, we outline the 41 SAPs identified from the chicken 
polyspliceosome.  Included are pre-mRNA interacting factors such as U2AF (Bennett et 
al., 1992; Kramer and Utans, 1991), PTB (Gil et al., 1991; Patton et al., 1991), and the 
cap binding complex proteins (Lewis et al., 1996).  We detected the majority of PRP19-
complex (NTC) related components as well, including homologues of Prp19p (Cheng et 
al., 1993; Russell et al., 2000), Syf1p (Russell et al., 2000), Syf2p (Russell et al., 2000), 
Syf3/Clf1p (Chung et al., 1999; Russell et al., 2000) ), Isy1p (Dix et al., 1999), 
SKIP/Prp45p (Albers et al., 2003; Figueroa and Haymn, 2004) and CDC5/Cef1p (Ben-
Yehuda et al., 2000; Tsai et al., 1999).  Interestingly, we detected a number of 
polypeptides which in yeast are snRNP associated, but have not been identified in 
purified metazoan snRNPs.  Among these polypeptides ar  putative orthologues of yeast 
Prp38p (Blanton et al., 1992), Prp39p (Lockhart andRymond, 1994), Prp40p (Kao and 
Siliciano, 1996), Aar2p (Gottschalk et al., 2001) and Luc7p (Fortes et al., 1999).  Other 
polypeptides exclusively contained in the purified chicken supraspliceosome include, 
NONO/p54nrb, PNN/Pinin and CWC22, which have been previously implicated in 
splicing (Kameoka et al., 2004; Ohi et al., 2002; Sakashita et al., 2004; Wang et al., 
2002)). 
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Table 3.2 Comparisons of spliceosome-associated proteins between 
supraspliceosomes purified from human or chicken cells with those purified from 
three in vitro assembled spliceosome experiments. 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
SAPs 
ENSGALG00000002514 SFPQ PSF • •   •   
ENSGALG00000002060 FUS TLS/FUS •     • • 
ENSGALG00000012468 PRPF39 PRP39 •         
ENSGALG00000010501 SNW1 SKIP/PRP45 • • • • • 
ENSGALG00000016704 CDC5L CDC5 • • •   • 
ENSGALG00000005012 RAB43 ISY1 •     • • 
ENSGALG00000008429 CRNKL1 CRN1 • • • • • 
ENSGALG00000009257 PRLG1 Prp46/PRL1 •     • • 
ENSGALG00000015061 CDC40 CDC40/PRP17 •     • • 
ENSGALG00000002002 BCAS2 SPF27 • •       
ENSGALG00000013919 PRPF19 PRP19 • • • • • 
ENSGALG00000010627 PRPF38A PRP38 • •       
ENSGALG00000005507 NONO p54nrb • •       
ENSGALG00000004555 RBM22 ECM2/RBM22 •     • • 
ENSGALG00000001247 SYF2 SYF2 •     • • 
ENSGALG00000000726 ELAVL1 ELAV/Hu • •   • • 
ENSGALG00000009001 - CWC22 •         
ENSGALG00000008149 EWSR1 EWSR1 (RBP) • •   •   
ENSGALG00000004705 BUD31 BUD31 •     • • 
ENSG00000076924 XAB2 SYF1 • •   • • 
ENSGALG00000001962 PTBP1 PTB • •   •   
ENSGALG00000011857 LUC7L2 LUC7/CROP •       • 
ENSG00000196504 PRPF40A PRP40 • •     • 
ENSGALG00000010167 PNN Pinin • •       
ENSGALG00000012813 PRPF4B Prp4K • •   • • 
ENSGALG00000000833 IK RED • •   • • 
ENSGALG00000001500 - SLU7 •     • • 
ENSG00000063244 U2AF2 U2AF65 • • • • • 
ENSGALG00000016198 U2AF1 U2AF35 • • • • • 
ENSG00000168066 SF1 SF1     • • • 
ENSGALG00000001034 C20ORF4 AAR2 •         
ENSGALG00000005525 SFRS1 SF2/ASF • •   • • 
ENSG00000102241 HTATSF1 TAT-SF1         • 
ENSGALG00000002087 NCBP1 CBC80 • •   • • 
ENSGALG00000006843 NCBP2 CBC20 • •   • • 
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Table 3.2 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
ENSG00000087087 - ASR2B       • • 
ENSG00000100296 THOC5 KIAA0983 • •   • • 
ENSG00000159086 C21ORF66 C21ORF66       • • 
ENSG00000126803 HSPA2 HSP70-2 • •   • • 
ENSGALG00000006512 HSPA8 HSP71 • •   • • 
ENSGALG00000009838 AQR Aquarius • •   • • 
ENSGALG00000002014 SMU1 SMU1 • •   • • 
ENSG00000163510 - CWC22       • • 
ENSGALG00000005623  TFIP11 SPP382 • •   • • 
ENSG00000137656 - CWC26       • • 
ENSG00000126698 DNAJC8 SPF31     • • • 
ENSG00000105705 SF4 SF4     • •   
ENSG00000113649 TCERG1 CA150   • • • • 
ENSGALG00000004626 RBM5 E1B-AP5 • •   •   
ENSG00000100056 DGCR14 DGCR14       • • 
ENSG00000105298 C19ORF29 C19ORF29       • • 
ENSG00000109536 FRG1 FRG1       •   
ENSG00000171824 EXOSC10 RRP6       •   
ENSG00000160799 CCDC12 CCDC12/CWF18       •   
ENSGALG00000011678 DNAJC13 DnaJ • •   •   
ENSG00000100813 ACIN1 Acinus   •   • • 
ENSG00000131051 RNPC2 HCC   •   • • 
ENSG00000084463 WBP11 WBP11   •   •   
ENSG00000196419 XRCC6 Ku70   •   •   
 
 
 
Supraspliceosome-associated hnRNPs  
 Polypeptides termed hnRNPs are those which are known t  interact with hnRNA 
and are highly abundant nuclear proteins.  We detected virtually all of the known 
hnRNP proteins in chicken cells, as well as other hnRNP-like proteins present in genome 
databases (Table 3.3).   
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RNA helicase-like proteins  
We identified a large number of DExH/D proteins in the purifications (Table 3.3).  
In addition to the RNA helicase-like polypeptides known to function in pre-mRNA 
splicing, such as DDX15/Prp43p (Arenas and Abelson, 1997; Fouraux et al., 2002; 
Martin et al., 2002), DHX8/Prp22p (Company et al., 1991; Schwer and Gross, 1998; 
Wagner et al., 1998), DDX46/Prp5p (Dalbadie-McFarland nd Abelson, 1990; O'Day et 
al., 1996; Will et al., 2002), DDX5/p68 and DDX17/p2 (Lin et al., 2005), UAP56/Sub2p 
(Kistler and Guthrie, 2001; Libri et al., 2001; Zhang and Green, 2001), and the snRNP-
associated helicases U5-200K/Brr2p (Lauber et al., 1996; Noble and Guthrie, 1996; 
Raghunathan and Guthrie, 1998) and U5-100K/Prp28p (Strauss and Guthrie, 1991; 
Strauss and Guthrie, 1994; Teigelkamp et al., 1997), we note a number of helicase-like 
proteins not previously implicated in pre-mRNA splicing contained in purified chicken 
supraspliceosomes.  These include 13 additional polypeptides with sequence motifs 
indicative of DEAD, DEAH or Ski2p-like helicase family members.  Although we do 
not have evidence for these proteins functioning in pre-mRNA splicing, the complete 
absence of DNA helicases in our preparations indicates  specificity which implies their 
function in RNA Pol II transcript processing. 
SR proteins 
Many splicing factors are rich in arginine and serin  residue including long 
stretches of alternating dipeptides termed SR domains.  These factors function at 
multiple steps in the pre-mRNA splicing pathway (Bourgeois et al., 2004).  We detected 
a number of these family members in our purifications from chicken cells (Table 3.3).  
Although there is not a complete set of known SR-proteins present, it is possible to 
conclude that, due to the means by which these complexes were purified and analyzed, 
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these SR proteins represent the major SR proteins functioning in these cells, and that the 
others function in the splicing of a smaller subset of pre-mRNAs. 
Other RNA binding proteins  
There were 18 polypeptides identified in our purified polyspliceosome material 
possessing sequence homology to polypeptides predicted to interact with RNA by virtue 
of RNA Recognition Motifs (RRM), double stranded RNA binding domains (dsRBD) 
and others (Table 3.3).  Some were identified previously, such as the ELAV/Hu protein 
involved in binding to AU-rich elements (Myer et al., 1997), the dsRBD-motif-containing 
NFAT45 and NFAT90, previously shown to exist in large nuclear complexes (Raitskin et 
al., 2001) and likely functioning in RNA Pol II transcript metabolism.  In Figure 3.3 we 
present a graphical representation of the various RNA binding proteins novel to our study 
and highlight their detectable sequence motifs. 
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Figure 3.3 Novel spliceosome-associated polypeptides with predicted RNA binding 
motifs.   
Polypeptides from Table 3.3 with no known function in the pre-mRNA processing 
pathway are shown with graphical representations of the various RNA interaction or 
other noted motifs listed at the bottom of the Figure.  
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Non-spliceosomal pre-mRNA processing factors 
In Table 3.1, we note the presence of 5’ end binding (CBC80 and CBC20) 
proteins.  In Table 3.3, the 3’ end processing factors (CSPF and CSTF), a 
comprehensive set of proteins shown to be involved in mRNA export including the 
TREX complex (THO1/HPR1, THO2, THO3/TEX1, UAP56 and ALY) (Strasser et al., 
2002) and export factors such as GLE2 (Blevins et al., 2003) and GLC7 (Gilbert and 
Guthrie, 2004) are reported.  We also note that a single component of the nonsense 
mediated decay (NMD) pathway, UPF1, (Mitchell and Tollervey, 2003) was identified in 
the chicken material.  As NMD is likely to be active only in a very small subset of pre-
mRNA processing complexes, we were surprised to see ev n a single polypeptide from 
this class of proteins. 
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Table 3.3 Polypeptides predicted to interact with the pre-mRNA, mRNA or the 
spliceosome and comparisons of those identified in the supraspliceosomes with those 
of spliceosomes formed in vitro. 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
RNA Helicase-like 
ENSGALG00000016461 DDX1 DDX1 • •       
ENSGALG00000016231 DDX3X DDX3 • •     • 
ENSGALG00000003532 DDX5 DDX5/p68 •   • • • 
ENSGALG00000012247 DDX17 DDX17/p72 • •   • • 
ENSGALG00000012147 DDX18 DDX18 •         
ENSG00000102786 DDX26 DDX26/HDB       •   
ENSGALG00000006974 DDX27 DDX27 •         
ENSGALG00000003030 DDX41 DDX41/ABSTRAKT •     • • 
ENSG00000123136 DDX39 DDX39   •       
ENSG00000145833 DDX46 DDX46/PRP5   •   • • 
ENSGALG00000008530 DDX48 DDX48 • •   • • 
ENSGALG00000004144 DDX50 DDX50/Gu-ß • •       
ENSGALG00000001186 DHX8 DHX8/PRP22 • •   • • 
ENSG00000135829 DHX9 DHX9/HELICASEA • •   • • 
ENSG00000137333 DHX16 DHX16/PRP2       • • 
ENSGALG00000005027 DHX30 DHX30 • •       
ENSGALG00000003658 DHX35 DHX35 •         
ENSG00000174953 DHX36 DHX36   •       
ENSGALG00000014709 SKIV2L2 SKIV2L2 • •   • • 
ENSG00000198563 BAT1 UAP56 • •     • 
                
hnRNP 
ENSGALG00000006160 HNRNPA0 hnRNPA0 • •       
ENSGALG00000011036 HNRNPA2B1 hnRNPA2/B1 • • • • • 
ENSG00000135486 HNRPA1 hnRNPA1 • • • • • 
ENSGALG00000009250 HNRNPA3 hnRNPA3 • •   • • 
ENSGALG00000014381 HNRNPAB hnRNPAB • •       
ENSG00000092199 HNRPC hnRNPC1/C2 • • • • • 
ENSG00000138668 HNRNPD hnRNPD0/AUF1 • •       
ENSGALG00000011184 HNRNPDL hnRNPD0 • •   • • 
ENSG00000169813 HNRPF hnRNPF       •   
ENSGALG00000006457 RBMX hnRNPG • •   •   
ENSGALG00000005955 HNRNPH1 hnRNPH1 • •   •   
ENSGALG00000003947 HNRNPH3 hnRNPH3 • •       
ENSGALG00000012591 HNRNPK hnRNPK • •   • • 
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Table 3.3 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
ENSG00000104824 HNRNPL hnRNPL • •   • • 
ENSGALG00000000377 HNRNPM hnRNPM • • • •   
ENSGALG00000015830 SYNCRIP hnRNPQ • •   • • 
ENSGALG00000000814 HNRNPR hnRNPR • •   • • 
ENSGALG00000010671 HNRNPU hnRNPU • •   •   
ENSGALG00000018665 - hnRNP novel •         
ENSG00000126457 HRMT1L2 HRMT1L2  •         
                
SR 
ENSG00000133226 SRRM1 SRm160       • • 
ENSG00000167978 SRRM2 SRm300       • • 
ENSGALG00000005525 SFRS1 SF2p33 •         
ENSG00000161547 SFRS2 SC35       • • 
ENSGALG00000000533 SFRS2 SFRS3SRp20 • •   • • 
ENSG00000116350 SFRS4 SRp75         • 
ENSGALG00000009484 SFRS5 SRp40 •       • 
ENSGALG00000000990  SFRS6 SRp55 • •   • • 
ENSGALG00000013825 SFRS7 9G8 • •   • • 
ENSGALG00000002487  SFRS8 SFRS8 •         
ENSG00000111786 SFRS9 SRp30   •   • • 
ENSGALG00000006531 SFRS10 SFRS10 • •     • 
ENSG00000116754 SFRS11 SRp54       • • 
ENSG00000153914 SFRS12 SFRS12   •       
ENSGALG00000004133 FUSIP1 SRrp35 • •       
                
RBP 
ENSG00000102317 RBM3 RBM3   •       
ENSGALG00000018992 RBM4B RBM4B/Lark •         
ENSGALG00000004626 RBM5 RBM5 •     •   
ENSGALG00000007017 RBM7 RBM7 •     •   
ENSG00000131795 RBM8A RBM8B   •       
ENSGALG00000013411 RBM14 RBM14 • •       
ENSG00000162775 RBM15 RBM15   •   • • 
ENSGALG00000002372 RBM15B RBM15B • •       
ENSG00000197676 RBM16 RBM16   •       
ENSGALG00000004555  RBM22 RBM22 •         
ENSG00000119707 RBM25 RBM25   •       
ENSG00000091009 RBM27 RBM27   •       
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Table 3.3 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
ENSGALG00000011038 CBX3 RNPS1 •       • 
ENSG00000033030 ZCCHC8 ZFP8   •   •   
ENSGALG00000006113 ZNF326 ZFP326 •         
ENSG00000179950 - PUF60   •   • • 
ENSG00000197381 ADARB1 ADAR1   •       
ENSG00000160710 ADAR ADAR2   •       
ENSGALG00000010952 - Requiem •         
ENSGALG00000011570 ILF2 NFAT45 • •   • • 
ENSG00000129351 ILF3 NFAT90 • •   • • 
ENSG00000169564  PCBP1 PolyrCBP •         
ENSGALG00000012225 CIRBP CIRBP • •       
ENSG00000056097 ZFR ZFR • •       
ENSGALG00000009427 TIAL1 TIA1 •         
ENSGALG00000001187 STRBP STRBP •         
ENSGALG00000005623  TFIP11 Tuftillin-IP • •       
ENSG00000136231 IGF2BP3 IMP3 • •   • • 
ENSG00000060138 CSDA CSDA       • • 
ENSG00000121774 KHDRBS1 SAM68   •       
ENSG00000126254 - Novel RRM   •       
ENSG00000132773 TOE1 TOE1   •       
ENSG00000142864 SERBP1 SERBP1   •       
                
Export/transcription/NMD 
ENSGALG00000014915 THOC1 THO1/HPR1 • •       
ENSGALG00000008507 THOC2 THO2 • •   • • 
ENSG00000051596 THOC3 THO3/TEX1 • •       
ENSGALG00000007237 THOC4 THO4/ALY • •   • • 
ENSGALG00000004571 PPP1CA GLC7/PPP1CA •         
ENSGALG00000002569 RAN Ran • •       
ENSG00000119392  GLE1L GLE1L   •       
ENSGALG00000007653 RAE1 GLE2/RAE1 • •       
ENSGALG00000003220 RENT1 UPF1/RENT •         
ENSG00000131795 RBM8A Y14/RBM8A • •     • 
ENSGALG00000002144 THRAP3 TRAP150 • •       
ENSG00000172660 TAF15 TAF15/RBP56 •         
ENSG00000162231 NXF1 TAP   •       
ENSG00000065978 YBX1 YBX1   •   • • 
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Table 3.3 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
ENSGALG00000010689 MAGOH Mago nashi • •     • 
                
3' end proc. 
ENSG00000071894 CPSF1 CPSF1       •   
ENSGALG00000010783  CPSF2 CPSF2 •         
ENSGALG00000016424 CPSF3 CPSF3 • •       
ENSGALG00000004714 CPSF4 CPSF4 •         
ENSGALG00000003084 CPSF5 CPSF5   •   • • 
ENSG00000111605 CPSF6 CPSF6       • • 
ENSGALG00000011685 CSTF3 CSTF-77 • •       
ENSGALG00000013943 FIP1L1 FIP1 •         
ENSG00000172239 PAIP1 PAIP1   •       
ENSG00000100836 PABPN1 PABPN1   • • • • 
ENSGALG00000003800 PABPC4 PABPC4   •       
 
 
Nuclear matrix and filament proteins  
Recent data from several laboratories indicates functio al interaction between the 
structural proteins of the nuclear matrix and the gene expression machinery (de Lanerolle 
et al., 2005).  We detected a number of such proteins including actin, spectrin, matrin3, 
numatrin, and lamin B (Table 3.4).  Although we cannot determine the functional 
relevance of the association of structural proteins with these endogenously formed pre-
mRNA splicing complexes, we note that a number of hnRNPs and other known splicing 
factors such as Prp19p (Gotzmann et al., 2000) were initially termed nuclear matrix-
associated proteins indicating an intimate relationship between the pre-mRNA processing 
machinery and the nuclear matrix.  Indeed it is an attractive hypothesis that pre-mRNA 
and mRNA are trafficked to the nuclear pore by means of the nuclear matrix. 
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Polypeptides novel to pre-mRNA splicing- SWI/SNF proteins and associated factors  
A recent report from Muchardt and colleagues has demonstrated the association 
of the SWI/SNF associated factor Brahma/SMARCA4 (Brm) with the splicing apparatus 
and its presence favors the inclusion of alternatively spliced exons (Batsche et al., 2006).  
The splicing-related Prp4-kinase, which is present in both the human and chicken 
supraspliceosomes, has been reported to phosphorylate both Brm and the splicing factor 
U5-102K/hPrp6 (Dellaire et al., 2002) providing further evidence that Brahma is 
functioning in Pol II transcript maturation.  In the purified chicken supraspliceosomes, 
Brahma/SMARCA4, and a number of other SWI/SNF-related polypeptides were 
identified (Table 3.4), all with high degrees of confidence given the depth of the peptide 
identification (Appendix A).  As this purification yielded no mass spectrometry data 
suggesting any chromatin-associated factors such as histone proteins, the DNA 
replication machinery or other DNA binding proteins, we have no reason to believe that 
these polypeptides are not specifically associating with the pre-mRNA processing 
complexes.  Further studies will illuminate the specific function of these polypeptides in 
pre-mRNA processing. 
Nuclear pore complex proteins  
In the chicken supraspliceosomes, we detected a small et of NUPs (Table 3.4).  
It will be interesting to see if these are functional interactions between maturing pre-
mRNA processing complexes and the nuclear pore, or if these polypeptides are 
promiscuously interacting with the supraspliceosomes.   
Cyclophillins 
In addition to the known snRNP-associated USA-CYP (Horowitz et al., 1997; 
Teigelkamp et al., 1998), we detected 5 additional potential disulfide isomerases co-
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purifying with spliceosomes from chicken (Table 3.4).  These proteins are important for 
folding and structural rearrangement. 
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Table 3.4 Structural, nucleoporin, and cyclophillin proteins present in the 
supraspliceosomes and in vitro assembled splicing complexes 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
Structural 
ENSGALG00000012533 MYH9 Myosin • •       
ENSGALG00000009126 TTN Titin •         
ENSGALG00000001381 ACTG1 Actin • •       
ENSGALG00000002478 MATR3 MATRIN3 • •   • • 
ENSGALG00000008677 VIM Vimentin • •       
ENSG00000117245 KIF17 Kinesin KIF17 •         
ENSGALG00000002197 NPM1 NUMATRIN • •   •   
ENSGALG00000014692 LMNB1 Lamin B • •       
ENSGALG00000013505 SYNE1 NuSpectrin • •       
ENSG00000140259 MFAP1 MFAP1       • • 
                
Chromatin modification 
ENSGALG00000000360 ARID1A ARID1A-SWI/SNF •         
ENSGALG00000013683 ARID1B ARID1B-SWI/SNF •         
ENSGALG00000010164 SMARCA2 SMARCA2 •         
ENSG00000127616 SMARCA4 Brahma/SMARCA4 •         
ENSGALG00000009913 SMARCA5 SMARCA5 •         
ENSGALG00000005983 SMARCB1 SMARCB1 •         
ENSGALG00000005048 SMARCC2 BRG1-SWI/SNF •         
ENSGALG00000005048 SMARCC1 SMARCC1 •         
ENSGALP00000010010 SMARCD1 SMARCD1 •         
ENSGALG00000000363 SMARCD2 SMARCD2 •         
ENSGALG00000002100 SMARCE1 SMARCE1 •         
                
Nucleoporins 
ENSGALG00000005714 PKD1 PKD1 (NUP assoc) •         
ENSGALG00000003830 NUP214 NUP214 • •       
ENSGALG00000012720 NUP153 NUP153 •         
ENSGALG00000005078 NUP210 NUP210 • •       
ENSG00000102900 NUP93 NUP93   •       
ENSG00000108559 NUP88 NUP88   •       
ENSG00000111581 NUP107 NUP107   •       
ENSG00000110713 NUP98 NUP98   •       
ENSG00000138750 NUP54 NUP54   •       
ENSG00000163002 NUP35 NUP35   •       
ENSG00000069248  NUP133 NUP133   •       
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Table 3.4 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
ENSG00000155561 NUP205 NUP205   •       
                
Cyclophillins 
ENSGALG00000013383 PPIE CYP-E •     • • 
ENSGALG00000004874 PPIH USA-CYP •         
ENSGALG00000014747 SDCCAG10 CYP16 •     •   
ENSG00000137168 PPIL1 PPIL1/CWF27 •     • • 
ENSG00000100023 PPIL2 PPIL2/CYP60 •     • • 
ENSG00000115934 PPIL3 PPIL3B       • • 
ENSG00000113593 PPWD1 PPWD1 •     • • 
 
 
3.3.2 Compositional comparison of chicken versus human supraspliceosome 
For purification of the human supraspliceosomes, we gently sonicated nuclei in a 
buffered low-salt solution.  After a short, low-speed centrifugation, the resulting nuclear 
extract was sedimented through a glycerol gradient and the material from a region 
corresponding to a sedimentation coefficient >200S was pooled (Figure 3.4A, 3.4B).  
We did not observe a peak sedimenting at a certain gr dient fraction due to the fact that 
the lnRNP particle is proposed to have one to eight repeating spliceosomal substructures. 
This material was incubated with anti-Sm epitope-reactive monoclonal antibody Y12 
covalently attached to Sepharose beads to bind Sm-protein-containing material to the 
affinity resin.  Remarkably, this treatment nearly quantitatively retained the detectable 
material from this region of the glycerol gradient, even after extensive washing indicating 
that the majority of the nuclear contents of this size, perhaps not surprisingly, are Sm-
antigen-containing complexes.  The lack of polyribosomes in the rapidly sedimenting 
material (as judged by the absence of 5S and 5.8S rRNAs and ribosomal proteins by mass 
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spectrometry) indicates that nuclei we prepare are not contaminated with cytoplasm. 
Preparatively-purified material was separated by SDS-PAGE gels of two compositions to 
better resolve the polypeptides (Figure 3.4C).  To demonstrate the specificity of this 
purification, gradient-separated supraspliceosomes were subjected to affinity 
chromatography using identical beads and identical washing and elution conditions, but 
lacking the Y12 antibody.  In Figure 3.5A and 3.5B, we show that from mock 
purification, there is not detectable coomassie-stained material in the resulting protein gel 
and no snRNAs are present. 
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Figure 3.4 Human supraspliceosome-associated polypeptides and snRNAs. 
RNA (A) and protein (B) were extracted from preparative glycerol gradient fractions and 
electrophoretically resolved through urea-PAGE (A) or SDS-PAGE (B) gels stained with 
silver (nucleic acid) or coomassie blue (protein).  Bar below B represents the fractions 
of the material pooled for immunopurification with Y12 antibody.  (C) Affinity-purified 
supraspliceosomal proteins run under two SDS-PAGE conditions to resolve either large 
or small polypeptides.  Gels were aligned to show all polypeptides in the affinity-
purified fractions and are delineated by the marking between them.  The entire gel lanes 
shown from the two gels in (C) were dissected and each gel slice was subjected to mass 
spectrometry protein identification.  The proteins dentified are reported under the Hs 
PS column in Tables 3.1-3.5 and 3.7. 
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Figure 3.5 Mock-purified HeLa supraspliceosomes. 
(A) Proteins from HeLa mock-purified polyspliceosome stained with coomassie blue G-
250.  (B) Ethidium bromide-stained nucleic acids from the fraction. 
 
 
By mass spectrometry we detected 177 distinct polypeptides in the HeLa 
supraspliceosome, however, the coverage of the major spliceosomal snRNP proteins was 
more complete for the chicken supraspliceosomes.  Polypeptides identified specifically 
from chicken supraspliceosome but not from HeLa supraspliceosome are summarized in 
Table 3.5. 
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No AT-AC specific splicing components were detected in the human complex, 
suggesting CLEP tagging and purification procedure is more sensitive than conventional 
antibody affinity chromatography.  We did not detect any snRNP biogenesis factors in 
the HeLa supraspliceosomes, but we note that the chicken cells were processed fresh, 
while the HeLa cells were obtained commercially and remained at 4˚C during shipment 
overnight.  This may disfavor the purification of these or even other factors (e.g. 
cyclophillins and chromatin remodeling proteins) in the case of the HeLa 
supraspliceosomes.  A substantial set of nucleoporins (NUPs) were present in the 
purified supraspliceosomes complexes from human cells.  NP40 was absent during the 
purification of the human complexes, which likely maintained the integrity of 
hydrophobic interactions which may stabilize the export complexes with the NUPs.   
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Table 3.5 Polypeptides identified in chicken supraspliceosomes but not in human 
supraspliceosomes 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe 
U2 snRNP 
ENSGALG00000013352 SF3B4 SF3b49 •   
ENSGALG00000016501 - SF3b14 •   
ENSGALG00000020000 SF3B5 SF3b10 •   
U2-snRNP associated 
ENSGALG00000006332 RBM17 SPF45 •   
ENSGALG00000008561 SMNDC1 SPF30 •   
ENSGALG00000003824 CHERP CHERP •   
U5, U4/U6 & U4/U6•U5 snRNP 
ENSGALG00000004874 PPIH USA-CYP •   
ENSGALG00000011931 NHP2L1 U4/U6•U5-15.5k •   
ENSGALG00000017396 TXNL4A U5-15K •   
AT/AC 
ENSGALG00000005162 RNPC3 U11/U12-65K •   
ENSGALG00000013005 C6ORF151 U11/U12-48K •   
Sm/LSM 
ENSG00000111987 LSM2 LSM2 •   
ENSGALG00000003385 LSM4 LSM4 •   
snRNP biogenesis 
ENSGALG00000010154 SIP1 SIP1  •   
ENSG00000119953 SMNDC1 SMNrp30 •   
ENSGALG00000003158 COIL Coilin •   
SAPs 
ENSGALG00000002060 FUS TLS/FUS •   
ENSGALG00000012468 PRPF39 PRP39 •   
ENSGALG00000005012 RAB43 ISY1 •   
ENSGALG00000009257 PRLG1 Prp46/PRL1 •   
ENSGALG00000015061 CDC40 CDC40/PRP17 •   
ENSGALG00000004555 RBM22 ECM2/RBM22 •   
ENSGALG00000001247 SYF2 SYF2 •   
ENSGALG00000009001 - CWC22 •   
ENSGALG00000004705 BUD31 BUD31 •   
ENSGALG00000011857 LUC7L2 LUC7/CROP •   
ENSGALG00000001500 - SLU7 •   
ENSGALG00000001034 C20ORF4 AAR2 •   
RNA Helicase-like 
ENSGALG00000003532 DDX5 DDX5/p68 •   
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Table 3.5 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe 
ENSGALG00000012147 DDX18 DDX18 •   
ENSGALG00000006974 DDX27 DDX27 •   
ENSGALG00000003030 DDX41 DDX41/ABSTRAKT •   
ENSGALG00000003658 DHX35 DHX35 •   
hnRNP 
ENSGALG00000018665 - hnRNP novel •   
ENSG00000126457 HRMT1L2 HRMT1L2  •   
SR 
ENSGALG00000005525 SFRS1 SF2p33 •   
ENSGALG00000009484 SFRS5 SRp40 •   
ENSGALG00000002487  SFRS8 SFRS8 •   
RBP 
ENSGALG00000018992 RBM4B RBM4B/Lark •   
ENSGALG00000004626 RBM5 RBM5 •   
ENSGALG00000007017 RBM7 RBM7 •   
ENSGALG00000004555  RBM22 RBM22 •   
ENSGALG00000011038 CBX3 RNPS1 •   
ENSGALG00000006113 ZNF326 ZFP326 •   
ENSGALG00000010952 - Requiem •   
ENSG00000169564  PCBP1 PolyrCBP •   
ENSGALG00000009427 TIAL1 TIA1 •   
ENSGALG00000001187 STRBP STRBP •   
Export/transcription/NMD 
ENSGALG00000004571 PPP1CA GLC7/PPP1CA •   
ENSGALG00000003220 RENT1 UPF1/RENT •   
ENSG00000172660 TAF15 TAF15/RBP56 •   
3' end proc. 
ENSGALG00000010783  CPSF2 CPSF2 •   
ENSGALG00000004714 CPSF4 CPSF4 •   
ENSGALG00000013943 FIP1L1 FIP1 •   
Structural 
ENSGALG00000009126 TTN Titin •   
ENSG00000117245 KIF17 Kinesin KIF17 •   
Chromatin modification 
ENSGALG00000000360 ARID1A ARID1A-SWI/SNF •   
ENSGALG00000013683 ARID1B ARID1B-SWI/SNF •   
ENSGALG00000010164 SMARCA2 SMARCA2 •   
ENSG00000127616 SMARCA4 Brahma/SMARCA4 •   
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Table 3.5 (Continued) 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe 
ENSGALG00000009913 SMARCA5 SMARCA5 •   
ENSGALG00000005983 SMARCB1 SMARCB1 •   
ENSGALG00000005048 SMARCC2 BRG1-SWI/SNF •   
ENSGALG00000005048 SMARCC1 SMARCC1 •   
ENSGALP00000010010 SMARCD1 SMARCD1 •   
ENSGALG00000000363 SMARCD2 SMARCD2 •   
ENSGALG00000002100 SMARCE1 SMARCE1 •   
Cyclophillins 
ENSGALG00000013383 PPIE CYP-E •   
ENSGALG00000004874 PPIH USA-CYP •   
ENSGALG00000014747 SDCCAG10 CYP16 •   
ENSG00000137168 PPIL1 PPIL1/CWF27 •   
ENSG00000100023 PPIL2 PPIL2/CYP60 •   
ENSG00000113593 PPWD1 PPWD1 •   
 
 
3.3.3 Compositional comparison of in vivo versus in vitro purified supraspliceosome 
The core machinery, including snRNPs, SAPs, and SR proteins, is well 
represented in the material derived from all purification schemes.  However, several 
polypeptides are exclusively contained in the supras liceosome-associated material, or 
exclusively contained in the in vitro purified spliceosomes.  We propose that this may 
result from the differences in procedure, or perhaps in the differences realized when 
analyzing a single intron-containing pre-mRNA versus all of the pre-mRNAs in a cell 
(Tables 3.1-3.4).  We note that in the spliceosomes purified from in vitro extracts, many 
of the hnRNPs, RNA helicase-like proteins, and RNA binding proteins were identified.  
However, perhaps owing to specific binding of some polypeptides to the bulk pre-mRNA 
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and not the single transcript used in the in vitro spliceosome assembly reactions, a greater 
number of these polypeptides were present in the supra pliceosomes.  
3.3.4 Pre-mRNA processing factors not present in any spliceosome purification 
To estimate the aggregate number of polypeptides partici ting in the nuclear pre-
mRNA processing pathway between all of the purifications, we have compiled a list of 
factors know to function in post-RNA Pol II transcript processing, but not present in any 
of the five purifications listed in Tables 3.1-3.5.  In Table 3.6, we outline this small list 
of factors.  The inability to be detected may be due to transient interaction with 
spliceosome, low abundance or correlated with the presence of an abundance hnRNP 
protein of similar molecular weight.  We have not included factors for which there are 
yeast homologues, but no identifiable human or vertebrate homologue in the genomic 
databases.   
 
Table 3.6 Known pre-mRNA processing proteins not present in any purified 
splicing complex. 
ENSEMBL accession #a HGNCb Polypeptidec 
ENSG00000095485 CWF19L1 CWF19 
ENSG00000152404 CWF19L2 CWF19 
ENSG00000165630 PRPF18 PRP18 
ENSG00000140829 DHX38 PRP16 
ENSG00000149532 - CFI-59K 
ENSG00000165494 PCF11 PCF11 
ENSG00000172409 CLP1 CLP1 
ENSG00000111880 HCAP1 HCE/CEG1 
ENSG00000146007 ZMAT2 SNU23 
ENSG00000108296 CCDC49 CWC25 
ENSG00000101138 CSTF1 CSTF-50 
ENSG00000101811 CSTF2 CSTF-64 
ENSG00000161981 C16ORF33 U11/U12-25K 
ENSG00000184209 - U11/U12-35K 
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3.3.5 Validation of ZFR as a bona fide spliceosome component 
To demonstrate the authenticity of a novel polypeptid  that co-purified with 
endogenous spliceosomes, we generated antiserum against ZFR (Table 3.3) and used it to 
specifically immunopurify ZFR-associated components.  In Figure 3.6A, we show that 
the ZFR polypeptide is present in very high molecular weight complexes that co-migrate 
with supraspliceosomal material.  In Figure 3.6B, we show that the anti-ZFR antiserum, 
but not the pre-immune serum or the Protein-A beads, immunoprecipitates the U1, U2, 
U4, U5 and U6 snRNAs.  As a positive control, we showed that antiserum directed 
against the known spliceosomal protein SR140, prepared nd analyzed under identical 
conditions, also immunoprecipitated all of the snRNAs.  We also tested for the presence 
of another pre-mRNA splicing factor, hPrp43 (DHX15), in the material immunopurified 
with anti-ZFR; Figure 3.6C shows that the specific antiserum, but not the pre-immune 
serum or the Protein-A beads, immunoprecipitates hPrp43p/DDX15.  This demonstrates 
that the novel spliceosome-associated factor ZFR is indeed associated with spliceosomal 
snRNAs and other spliceosomal proteins. 
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Figure 3.6 The novel Zn finger protein ZFR is a bona fide spliceosomal component.  
 (A)  ZFR sediments with the 200S particle in glycerol gradients.  HeLa nuclear 
extract was subjected to glycerol velocity gradient sedimentation analysis as in Figure 2.  
Proteins from the indicated fractions were electrophoresed through SDS-PAGE gels and 
subjected to western blot analysis using anti-ZFR antiserum.  The bar below the gel 
denotes the 200S region.  (B)  ZFR is specifically associated with spliceosomal 
snRNAs.  Equal amounts of HeLa nuclear extract were incubated with protein-A beads 
(beads), pre-immune serum and protein-A beads (pre-immune), anti-ZFR antiserum and 
protein-A beads (anti-ZFR) or anti SR140 antiserum and protein-A beads (anti-SR140) 
according to the Materials and Methods.  Recovered nucleic acids were subjected to 
northern blot analysis and probed with antisense probes to human snRNAs (identities 
noted to the right of the Figure).  (C)  ZFR is specifically associated with complexes 
containing spliceosomal proteins.  Immunoprecipitation conditions and lanes are as 
described in (B).  Proteins were subjected to western blot analysis using hPrp43 
antiserum. 
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3.4 DISCUSSION 
Affinity purification of the SmD3-associated proteins from DT40 cells has 
allowed us to probe more deeply into the general pre-mRNA processing machinery 
present in vertebrate cells.  Indeed, when combined with the data from in vitro 
assembled spliceosome characterization and known splicing factors not detected in any 
complexes previously purified, we show there are at l st 305 polypeptides involved in or 
present during the processing of nuclear pre-mRNA.  In Figure 3.7, I present a 
schematic model of the pre-mRNA processing pathway in vivo that encompasses the 
concept of the supraspliceosome.  
What is perhaps most remarkable about our results is he fact that, despite the 
operationally distinct purification strategies, the basal pre-mRNA processing machinery 
required to effect the removal of a single intron in vitro is not significantly different than 
that purified from complex mixtures of all of the pre-mRNAs in a vertebrate or human 
nucleus.  The major differences in composition betwe n the previous purifications and 
the one described herein involve 1) polypeptides predicted by sequence homology to 
interact with the pre-mRNA 2) the depth of coverage for polypeptides involved in export 
and 3’ end processing, and 3) polypeptides which may require that the pre-mRNA in 
these complexes follow the path of RNA Pol II transcription and nuclear trafficking, such 
as the SWI/SNF complexes, structural proteins and nucleoporins.  Two possible classes 
of polypeptides may exist that are not detected in our preparations.  First are those that 
are underrepresented because they may interact with only a small number of pre-mRNAs, 
such as intron-or exon-specific binding proteins.  The other class of proteins which may 
participate in pre-mRNA splicing but is absent from ur analysis might include tissue-
specific developmental stage-specific factors which would not be present in our bulk 
supraspliceosome preparation due to the use of only two cells types. 
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Figure 3.7 Model of the vertebrate supraspliceosomes in gene expression.  
(A) Co-transcriptional assembly of spliceosomes, 5’ end modification machinery and 
other pre-mRNA binding factors with RNA polymerase II transcripts. (B)  Released 
transcript contains numerous spliceosome moieties, spliced and un-spliced exons and 5’ 
cap-binding complex and 3’ end processing factors.  (C)  Mature mRNA contains RNA 
binding proteins, 5’- and 3’-end stabilizing factors, and proteins which promote the 
export of the mRNA.   
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Our mass spectrometry peptide data revealed several intriguing and novel 
polypeptides in these complexes.  We found chicken homologues of the yeast splicing 
factors Prp38p, Prp39p and Aar2p, previously unannotated in purified pre-mRNA 
splicing complexes. 
A number of uncharacterized RNA binding proteins were identified in our 
purifications.  Recent studies have revealed the functions of some of the RNA binding 
protein.  RBM4 has been shown as alternative splicing regulator that favors intron 
inclusion (Kar et al., 2006; Lai et al., 2003).  Guo et al. demonstrated that RBM7 
interacted with splicing factor 3b subunit 2 (SAP145), and with the splicing regulator, 
SRp20a, suggesting a role in pre-mRNA processing pathway (Guo et al., 2003).  
One of the novel polypeptides of interest in the endogenous splicing complexes is 
RAT1p/XRN2.  Rat1p has been identified as a nuclear 5’ to 3’ exonuclease (Amberg et 
al., 1992; Johnson, 1997; Kim et al., 2004) and involved in many RNA processing 
pathways such as rRNA processing, snoRNA biogenesis, mRNA export, and 
transcription termination.  Interestingly, when our lab characterized the temperature 
sensitive mutant prp27-1, initially identified from Abelson lab (Vijayraghav n et al., 
1989), it was shown to be allelic to RAT1 (Gupton et al., submitted).  This prp27-1 
mutant resulted from a single amino acid change in a conserved yet uncharacterized 
domain.  At non-permissive temperature, this mutant c uses severe post-splicing intron-
accumulation phenotype, suggesting its role in spliceosome disassembly or intron 
turnover pathways.  A bank of rat1 mutants has been created to further determine the 
domain specificity to intron turnover.  Another novel polypeptide, Tra2 collaborates 
with other SR proteins and regulate alternative splicing of gonadotropin releasing 
hormone pre-mRNA (Paradis et al., 2007; Park et al., 2006). 
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Furthermore, two uncharacterized AAA ATPases, ATAD3 and ATAD3B that 
may perform chaperone-like functions and assist assembly or disassembly of protein 
complexes were identified in both chicken and human supraspliceosome.  We report the 
identity of all the novel factors in Table 3.7 
Although we cannot completely eliminate the possibilities that there may be 
contaminants present in our preparations, our results are validated by evidence from our 
lab and other researchers that proteins Brahma, Rat1, and Tra2α have a novel role in 
splicing that were not detected previously in the in vitro-assembled spliceosome. 
With the introduction of the CLEP tagging technology to novel proteins in DT 40 
cells or to more cell types (Chen et al., 2006) andusing small interfering RNA (siRNA) 
for gene silencing (Paul et al., 2002) in other cell lines or creating knockout in DT40 cells 
(Winding and Berchtold, 2001), it will be possible to characterize these factors more 
rapidly. 
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Table 3.7 Novel polypeptides present in the supraspliceosomes and in vitro 
assembled splicing complexes 
ENSEMBL accession #a HGNCb Polypeptidec 
Gg 
PSd 
Hs 
PSe Nf Rg Zh 
Novel or unknown to splicing 
ENSGALG00000011351 HSP90AA1 HSP90α • •       
ENSGALG00000010175 HSP90AA2 HSP90ß • •       
ENSGALG00000012726 HSP90B1 HSP108 • •       
ENSGALG00000009967 LRPPRC LRP130 •         
ENSGALG00000003693 MACF1 Macrophin •         
ENSGALG00000007705 NCL Nucleolin •         
ENSGALG00000015933 C21ORF66 GCRBF •         
ENSGALG00000008454 - NOP58 •         
ENSGALG00000009061 ACTL6A BAF53A •         
ENSGALG00000007520 SSRP1 FACT80 • •       
ENSGALG00000015821 CCT8 TCP1-theta •         
ENSGALG00000014500 NOL5A Nol5A/NOP56 •         
ENSGALG00000005624 MED12 TRAP230 •         
ENSGALG00000010973 TRA2A TRA2a • •       
ENSGALG00000008372 XRN2 RAT1 • •       
ENSG00000197157 - SND1 • •       
ENSGALG00000001948  SAFB2 SAFB/HSP27 • •       
ENSGALG00000003177 BRD8 BRD8 • •       
ENSGALG00000010699 - FOG •         
ENSGALG00000005177 C9ORF10 C9ORF10 • •       
ENSGALG00000002653  - ELG • •       
ENSGALG00000016949 WBP4 WBP4 •         
ENSGALG00000004133 FUSIP1 Fus IP • •       
ENSGALG00000017384  ERH ERH • •       
ENSG00000079246 XRCC5 Ku80   •       
ENSG00000182562 ATAD3A 
ATAD3A (AAA 
ATPase) • •       
ENSGALG00000001515 ATAD3B 
ATAD3B (AAA 
ATPase) • •       
ENSG00000108588  CCDC47 CCDC47   •       
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Chapter 4: Gene targeting in mouse embryonic stem cells and 
generation of mice carrying an epitope tag 
4.1 BACKGROUND  
Mouse embryonic stem cells are pluripotent cells derived from the inner mass of 
preimplantation blastocyst-stage embryos.  Bradley et al. showed that ES cells had the 
capacity to colonize the reproductive organs of chimer c mice and transmit genetic 
information to progeny even after having been cultured for a long period of time in vitro 
(Bradley et al., 1984; Robertson et al., 1986).  This observation paved the way for the 
generation of transgenic mice by manipulating genes i  ES cells.  Alteration of the 
mouse genome by homologous recombination in ES cells was first achieved in 1987.  
Doetschman et al. and Thomas et al. were able to show that by homologous 
recombination, segments of the mouse genome could be disrupted or replaced 
(Doetschman et al., 1987; Thomas and Capecchi, 1987).  The ability of ES cells to enter 
the germline after genetic manipulation in culture and differentiate into different cells 
types depends on the conditions in cell culture.  To keep the ES cells in an 
undifferentiated state in the cell culture system, they are co-cultured with a feeder layer 
of cells, typically mouse embryonic fibroblasts coated on the inner layer of culture dishes 
and/or the addition of leukemia inhibitory factor to the culture media (Hogan, 1994; 
Pease and Williams, 1990).  The feeder layer not only provides cellular contact for the 
maintenance of the ES cells in the undifferentiated state but also releases nutrients to the 
media.  Transgenic mice, knockout and knockin mice, generation is based on ES cell-
derived techniques.  Coupled with Cre/lox-based approaches, tissue-specific and 
conditional knockouts can be obtained, which are particularly useful with embryonically 
lethal genes.  Gene-targeting has become a feasible tool to produce mice with alterations 
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in specific genomic loci.  It is an important tool t study the function of individual 
proteins, biological complexes and pathways [see revi w in (Muller, 1999)]. 
In this chapter, I show how I applied the CLEP technique (described in Chapter 2) 
to mouse embryonic stem cells and describe the transgenic mice that were generated.  I 
created two targeting constructs for two different spliceosomal proteins for gene targeting 
in mouse ES cells.  First, I inserted a TAP tag at the carboxyl-terminus of the U4/U6•U5 
(tri-snRNP) associated protein, SART-1 (squamous cell carcinoma antigen recognized by 
T-cells 1; also known as U4/U6•U5-110K).  Secondly, I chose a U5-associated protein 
U5-220K and inserted a polyhistidine tag at its carboxyl-terminus. 
 SART1 was identified previously as a gene encoding a protein recognized by 
cytotoxic T cells of squamous cell carcinoma patients (Shichijo et al., 1998).  
Expression of SART1 might be a potential tool for specific immunotherapy of patients 
with tumors.  It is also identified as an autoantigen which can interact with IgE 
autoantibodies from patients suffering from actopic dermatitis (Valenta et al., 1998).  
Subsequently, Makarova et al. showed that SART1 was an SR-related U4/U6•U5 tri-
snRNP protein.  SART-1 encodes a protein of 800 amino acids and a predicted 
molecular weight of 90,263 kDa; however, the slower migration behavior of SART1 in 
SDS-PAGE gels, corresponding to an molecular weight of 110 kDa was assumed due to 
the glutamic acid rich region comprising amino acids 450-600 (Makarova et al., 2001).  
It is orthologous to the yeast Snu66p and is important for the recruitment of the 
U4/U6•U5 tri-snRNP to the pre-spliceosome and the assembly of mature spliceosome 
(Stevens and Abelson, 1999)  
U5-220K, an ortholog of yeast Prp8p, is the largest and most highly conserved U5 
snRNP associated protein which in the course of splicing contacts U5 snRNA, U6 
snRNA, the branchpoint of pre-mRNA, the 5’ and 3’ splice sites in the intron as detected 
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by photochemical cross-linking.  It interacts with several splicing proteins and is 
involved in both the first and second step of splicing [reviewed in (Grainger and Beggs, 
2005)].  
The mice carrying CLEP tags will not only allow us to characterize spliceosomes 
from different tissues but also perform biochemical and histological analyses from the 
native, endogenous pre-mRNA splicing machinery in a living animal. 
4.2 MATERIALS AND METHODS  
4.2.1 Targeting vector construction 
The targeting vector creation is described as in section 2.2.1.  The 
oligonucleotides for creating the SART1-TAP targeting vector and U5-220K-(His)8 are 
shown in Table 4.1. 
Table 4.1 Oligonucleotides used for targeting vector construction in ES cells 
Targeted gene                       Oligo sequence 
mSART-1A 5’- GCGGCCGCGAAATAGGAGCAGCTGTGAACATGG-3’ 
mSART-1B 5’- TCTAGAGGATCCTTTGGTGATGGTGTTCCTGCAGGG-3’ 
mSART1C  5’-GTCGACAGCCGCCCTCCTCCCTGGCCCAGATG-3' 
mSART1D 5’-TTAATTAAGATCCACAGGCACAGCCGAGAACAC-3’ 
mSART1E 5’-ATCGATTGGCTAGTGATGGTTGTGCAGGAGTG-3’ 
mSART1F 5’-TGATCAATTGACCCATTCTGTCAATGGGTGTG-3' 
mU5-220KA 5'-GCGGCCGCGGCTAAAAATATTTTTGTATGTAGG-3' 
mU5-220KB 5'-AAGCTTCTAGTGGTGATGATGATGATGATGATG 
 GGCATAGAGGTCCTCTCTGTCTGCAG-3' 
mU5-220KC 5'-GTCGACTTACTTCCTTCTGCTTCAGATCCCC-3' 
mU5-220KD 5'-TTAATTAACGGGTCCGAAGCGGCGTGCCAGCCC-3' 
mU5-220KE 5'-CTCGAGACGCGGCGGCTGGGCTGGTGCCACTAG-3' 
mU5-220KF 5'-GCTAGCTCCAGTCCCTCACCGCTGGAAGTACGC-3' 
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4.2.2 ES cell electroporation and generating transgenic mice 
To generate transgenic mice using mouse ES cells, SM1 mouse embryonic stem 
cells (129S6) were electroporated with the linearized targeting construct.  ES clones 
which survived in double selection media containing G418 and ganciclovir were isolated, 
expanded into 6-well plates and grown until confluent.  PCR analysis of purified 
genomic DNA (DNeasy tissue kit, Qiagen) was performed to screen for epitope-tag 
insertion into the correct chromosomal locus.  To generate transgenic mice (Illustration 
4.1), correctly targeted ES clones were microinjected into E3.5 C57Bl/6 blastocysts and 
implanted into (CD1) pseudopregnant females.  Resulting chimeric males were mated to 
C57Bl/6 females for germline transmission of the altered allele.  The resulting agouti 
mice were screened for the SART1-TAP with western blot analysis.  Male and female 
heterozygotes carrying the epitope tag in one of the alleles are mated to one another to 
generate homozygotes carrying TAP tags in both alleles. 
 All mice were housed in accordance with protocols approved by the Animal 
Care and Use Committee of the University of Texas at Austin. 
4.2.3 Screening for the epitope-tagged gene by PCR and RT-PCR analysis 
Genomic DNA was extracted (DNeasy tissue kit, Qiagen) from G418- and 
ganciclovir-resistant ES colonies to screen mouse ES cells positive for mSART-1-TAP.  
PCR reactions were performed using one oligonucleotid  designed outside the targeting 
construct region (PCR5) and the other one inside th targeting vector (PCR3): 
mSARTPCR5 (5’-CCTCTCACTGCCTCTCCTGCTGCGGGG-3’) and mSARTPCR3 
(5’- GAGGAGGCTCAGCGACTTGCCAGATGG-3’).  The genotypes of agouti mice 
and progeny were screened for evidence of targeted insertion of the TAP tag using RT-
PCR analysis from whole blood total RNA (Mouse RibopureTM-Blood RNA Isolation 
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Kit, Ambion) with oligonucleotides (RTPCR5) mSARTPCR5 (5’-
GCTCCAGGAGAAGCAGAAGGC-3’) and (RTPCR3) mSARTRTPCR3 (5’ 
CTAACCTTAGACAGCAGCACAACCAAGAG3’).  The oligonucleotides for 
screening the insertion of polyhistidine tag into U5-220K gene were mU5220KRTPCR5 
(5’-CAACAACCCCAAAGGCTACCTACCCTCGC-3’) and mU5220KRTPCR3 (5’-
GTTCAAGAGGCTCCAGGCTTTGGGGATC-3’). 
 
 
 
 
 
 
 
 
 
 
 96 
 
Illustration 4.1 Producing transgenic mice carrying an epitope tag 
Embryonic stem cells carrying a targeted epitope tag are injected into the blastocyst-stage 
embryo from a black mouse strain and then placed in surrogate mothers.  If the ES cells 
can survive and proliferate in the embryos, the newborns will become chimeric carrying 
cells from two mouse strains.  Chimeric mice are thn mated to black mice and the 
resulting agouti progeny are screened for evidence of the targeted insertion of the epitope 
tag.  Male and female heterozygotes carrying an epitope tag in one of the alleles are 
mated to one another to generate homozygotes carrying epitope tags in both alleles. 
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4.2.4 Western blotting analysis   
Mouse ES cells and organs from sacrificed mice were p ocessed by 
homogenization in LDS sample buffer.  Approximately 50 mg of each organ was 
homogenized in 1 ml of SDS-PAGE loading buffer.  The agouti mice expressing 
SART1-TAP were confirmed by western blot analysis from tails homogenized in the 
LDS sample buffer.  Homogenized samples (20 µl) were electrophoresed through SDS-
PAGE gels and transferred to a nylon membrane for western blotting analysis.  
Peroxidase-antiperoxidase (PAP) antibody (Sigma) was used for detecting TAP tagged 
proteins. 
4.2.5 Preparation of extracts from liver nuclei and brain nuclei 
The preparation of extracts was performed as previously described (Lu et al., 
1998) with some modifications.  Four livers and four cerebra were collected on ice, 
washed with 1X PBS and cut into small pieces in ice-cold buffer A [1.3 M sucrose, 1 mM 
MgCl2, 10 mM potassium phosphate, (pH 6.8)].  The small pieces were homogenized 
into 8 vol of buffer A containing 0.2 mM PMSF, 1 µg/ml leupeptin, and 1 µg/ml 
pepstatin in a dounce homogenizer with 10 strokes on ice.  The homogenate was filtered 
through 2 layers of cheesecloth and centrifuged at 1000 x g for 20 minutes.  The 
resulting pellets were then suspended in a 2 ml of ice-cold buffer A containing 0.2 mM 
PMSF, 1 µg/ml leupeptin, and 1 µg/ml pepstatin and homogenized again in a dounce 
homogenizer with 10 strokes.  The resulting suspension was mixed with 3.5 vol of ice-
cold buffer B [2.4 M sucrose, 1 mM MgCl2, 10 mM potassium phosphate, (pH 6.8)] and 
centrifuged at 100,000 x g for 1 hour.  The white nuclear pellet was suspended in 2 ml 
of low-salt buffer (30 mM Tris-HCl, 125 mM KCl, 5 mM MgCl2, 0.5% Triton-X100, 
0.15mM spermine, 0.05mM spermidine, and 0.2 mM PMSF), and sonicated at the 
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maximum output, twice for 20 seconds on ice with 1 minute in ice between sonications.  
The sonicated mixture was centrifuged at 5000 x g for 15 seconds and the supernatant, 
the nuclear fraction, was used for TAP purification as described in section 2.2.7.  
4.3 RESULTS  
4.3.1 Live mammals carrying CLEP tags 
4.3.1.1 Mice carrying SART1-TAP 
 After construction and clone validation, the targeting vector is linearized at an 
appropriate site upstream of the AB fragment (usually NotI) or downstream of the EF 
fragment (if not using ganciclovir selection).  The SART1-TAP targeting vector was 
linearized with NotI and electroporated into mouse ES cells.  After selection with G418 
and ganciclovir, one hundred forty one resistant colonies were selected and expanded.  
The presence of correctly targeted cells was tested by PCR using one oligonucleotide 
primer designed outside the targeting region (PCR5 in Figure 2.1) and one 
oligonucleotide primer designed inside the targeting vector (PCR3 in Figure 2.1).  Seven 
out of 141 ES cell clones were positive for the SART1-TAP construct (Figure 4.1A) and 
all seven were positive for the TAP tag of an approriately sized band (~130 Kd) by 
western blotting (Figure 4.1B).  Three chimeric mice were produced from injected 
blastocysts and tissue samples from brain, heart, kidney and spleen were analyzed for 
SART1-TAP by western blotting.  While wild-type mice were negative for TAP signal, 
the chimeric mice were positive in all tissues analyzed (Figure 4.1C).   
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Figure 4.1 Targeted SART1-TAP in ES cells and live mice.   
(A) Detection of SART1-TAP targeted mouse ES cell clones by PCR.  Wild-type and 
targeted alleles are noted.  (B) Western blot analysis of 5 of the 7 mouse ES cell clones 
positive for SART1-TAP from [A].  The 130Kd SART1-TAP is noted.  (C) Western 
blot analysis of SART1-TAP from organs of the mice generated from the mouse ES cells. 
Left panel, wild-type untagged mouse organs, right panel, SART1-TAP mouse organs. 
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Chimeric mice were mated to black mice which resulted in 11 agouti progeny.  
Six out of eleven agouti mice showed positive signals for SART1-TAP of an 
appropriately sized 130KDa band (Figure 4.2A).  The genotype of progeny from agouti 
mice was determined by RT-PCR from whole blood RNA using one oligonucleotide 
primer designed outside the targeting region and one inside the 3’UTR which is the same 
in the targeted and wild-type loci.  The wild-type mice contain two wild-type alleles, the 
heterozygotes contain one wild-type allele and one targeted allele, which is 590- 
nucleotides larger due to the tag and the homozygotes contain two targeted alleles (Figure 
4.2B). 
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Figure 4.2 Targeted SART1-TAP in agouti mice and their progeny. 
(A) The genotypes of agouti mice were determined by western blot analysis from tails 
homogenized in LDS sample using peroxidase-antiperoxidase (PAP).  We generated 11 
agouti mice; six out of eleven agouti mice showed positive signals of SART1-TAP.  
(B) RT-PCR analysis of progeny from SART1-TAP transgenic mice.   
Oligonucleotide primers designed upstream of the stop codon and within the 3’UTR were 
used to identify wild-type, heterozygote SART1-TAP or homozygote SART1-TAP mice.   
 
 
4.3.1.2 Mice carrying U5-220K-(His)8 
Utilizing the method described above, a polyhistidine tag (His)8 was inserted into 
the carboxyl terminus of U5-220K.  Two out of one hundred and thirty one ES cell 
colonies were positive for a HIS tagged U5-220K by RT-PCR of RNA (Figure 4.3A) and 
1 of 3 agouti progeny from HIS-tagged chimeras showed insertion of HIS-tag in one of 
the chromosomes (Figure 4.3B).  Unfortunately, by sequencing analysis, insertion of the 
polyhistidine tag inhibited the splicing of the last intron of U5-220K, leading to the 
accumulation of U5-220K mRNA containing the last intro  sequence.  U5-220K mRNA 
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containing the last intron sequence was not able to express polyhistidine tag for 
purification due to the presence of a stop codon within the intron sequence. 
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Figure 4.3 Targeted U5-220K-(His)8 in ES cells and in agouti mice.  
Correctly targeted U5-220K-(His)8 were screened by RT-PCR analysis.  The PCR 
fragments containing the last intron sequence were not d. 
 
 
4.3.2 Purification of SART1-associated proteins from brain and liver cells 
Splicing regulation, particularly alternative splicing, in a specific tissue or 
developmental stage contribute to functional complexity in the genome (Xu et al., 2002).  
Epitope tagging of proteins at the native chromosomal loci of genes in mice provides a 
useful tool to study the expression and organization of the gene expression machinery 
during different stages of development and in different tissues.  In addition, nuclear 
extracts derived from differentiated tissue serve as a useful tool to identify regulatory 
processing factors that are physiologically significant.  By purifying pre-mRNA 
processing complex from the livers of SART-1-TAP tagged homozygote, we will 
produce the in vivo assembled particles, which will provide great information and 
application to the study of tissue-specific regulatory mechanisms. 
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Liver and brain cells were first used for purification because of their relatively 
large biomass.  Moreover, other researchers have succe sfully purified proteins from 
liver cells or prepared splicing-active extracts from brain cells in mice/rats (Grabowski, 
2005; Lu et al., 1998).  Using similar nuclei extrac ion methods combined with TAP 
purification, I tried to purify SART1-associated proteins from brain and liver.  For brain 
samples, after running purified fractions on the SDS-PAGE gels, the protein bands 
looked exactly the same as that from wild type, non-tagged mice, suggesting no 
polypeptides specifically associated with SART1 were purified with this purification 
method (Figure 4.4); however, according to my western blotting analysis of brain tissue 
samples, I was able to identify the presence of SART1-TAP proteins in brain (Figure 
4.1C).  I conclude that SART1 proteins are not abundant enough for purification in brain 
tissue but can be detected by western blot analysis.  This result is supported by the 
database of gene expression pattern in mouse brains from Allen Institute for Brain 
Science/Allen Brain Atlas, as no SART1 expression was noted by in situ RNA 
hybridization (Figure 4.5).  Alternatively, the yeast homolog of SART1, Snu66p, is not 
essential in yeast but disruption of SNU66 confers a cold-sensitive phenotype (Stevens et 
al., 2001). This data suggests that SART1 may not be an essential splicing factor in brain.  
For the liver samples, I was able to purify the poly eptides specifically interacting with 
SART1 and U4, U5, and U6 snRNAs were present in the purified components (Figure 
4.6). These polypeptides will further be confirmed and validated by mass spectrometry. 
 
 
 
 105 
 
  
Figure 4.4 SART1-associated polypeptides in mouse brain. 
Calmodulin elution from a mock purification in whic WT type (non-tagged) mice brain 
samples was subjected to the TAP purification as background control in lane 1.  TEV 
elution, calmodulin beads flow through, and calmodulin elution from SART1-TAP 
homozygote brain samples were loaded in lane 2, 3, and 4, respectively. 
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Figure 4.5 SART1 and Prp8f expression in brain. 
SART1 (A) and Prpf8 (B) expression level were detected by RNA in situ hybridization. 
Expression of SART1 was not detected compared to that of another splicing factor Prpf8. 
The images were adapted from:  
http://www.brain-
map.org:80/viewImage.do?imageId=76074004&coordSystem=pixel&x=5088.5&y=3464
.5&z=7.86086272968458&initExp=y 
http://www.brain-
map.org:80/viewImage.do?imageId=68250086&coordSystem=pixel&x=5384.5&y=3240
.5&z=7.42873061565605&initExp=y  
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Figure 4.6 SART1-associated polypeptides and RNA inmouse liver. 
(A) Calmodulin elution from a mock purification in which WT type (non-tagged) mice 
liver samples were subjected to the TAP purification as background control in lane 1.  
TEV elution, calmodulin beads flow through, and calmodulin elution from SART1-TAP 
homozygote liver samples were loaded in lane 2, 3, and 4, respectively.  Polypeptides 
present only in the calmodulin fractions but not in he control were noted as arrows. (B) 
U4, U5, and U6 snRNAs were noted in the purified complex. 
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4.4 DISCUSSION  
These CLEP procedures will be of great use where circumstances require that the 
gene of interest be controlled by its native promoter, especially in live animals where 
expression of proteins at inappropriate levels can lead to developmental defects or 
unwanted interactions.  CLEP tagged animals should also prove useful for the study of 
virtually any process and serve as a biochemical tool to study the organization of protein 
complexes during different stages of development and in different tissues, especially 
those of disease relevant gene products.   
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Chapter 5: Induction of a Severe Autoimmune Response by 
Modification of SART1 (U4/U6•U5-110K) in Mice 
5.1 BACKGROUND  
Inappropriate autoimmune responses result from the breakdown of self-tolerance 
in which the immune system is not able to distinguish self antigens from foreign antigens.  
In healthy individuals, several tolerance mechanisms, working independently but in 
concert, maintain the balance between activation of inflammatory responses and 
prevention of autoimmunity (Gregersen and Behrens, 2006).  These mechanisms include 
clonal anergy, clonal deletion and peripheral suppression, such as immune suppression by 
natural T regulatory (Treg) cells and dysregulation of cytokines (Heath et al., 1996; 
O'Shea et al., 2002; Takahashi and Sakaguchi, 2003).  
Over the past few years, the discovery of functionally distinct subsets of 
lymphocytes has expanded our knowledge regarding the maintenance of self-tolerance.  
For example Treg cells, expressing the cell surface markers CD4 and CD25 and the 
transcription factor FoxP3, play a critical role in suppression of the activity of effector T 
cells (Asano et al., 1996; Fontenot et al., 2003; Randolph and Fathman, 2006).  
Imbalances in effector and regulatory T cells leads to autoimmune diseases (Torgerson, 
2006).  Another subset of lymphocytes, the marginal-zone (MZ) B cells, is located at the 
blood-lymphoid interface.  These cells are enriched with self-reactive clones and are 
proposed to initiate autoantibody production (Wellmann et al., 2001; Zeng et al., 2000).   
Increases in MZ B cells occur in lupus-prone mice even before clinical 
manifestation of the disease (Wither et al., 2000).  Multiple activated pathways 
contribute to the process of autoimmune disease and inappropriate immune response is 
often the cause of organ-specific or systemic damage (Marrack et al., 2001).  The cause 
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of autoimmune diseases is not fully understood, but in some cases it can be triggered by 
exposure to drugs, microorganisms, or by environmental causes in people with a genetic 
predisposition to autoimmunity (Marrack et al., 2001).  
A high titer of autoantibodies is a diagnostic hallmark in many autoimmune 
diseases (von Muhlen and Tan, 1995).  Anti-nuclear antibodies, including several 
populations of antibodies with different specificities, have been identified in patients with 
various autoimmune diseases (von Muhlen and Tan, 1995).  Among these anti-nuclear 
antibodies, is a spectrum of antibodies to small nuclear ribonucleoproteins (snRNP) 
involved in pre-mRNA splicing, such as anti-Sm and anti-U1 RNP (Hoet et al., 1993).  
Non-spliceosomal RNP components Ro/SSA, and La/SSB are also targets of 
autoimmune-related antibody responses (White et al., 1981; Wolin and Steitz, 1984).   
It is intriguing that RNP components are common targets of the autoimmune 
response as recent studies have shown these RNP components not only initiate 
autoantibody production but also perpetuate autoimmunity (Marshak-Rothstein, 2006; 
Martin and Elkon, 2005).  These RNPs become immunoge ic during apoptosis-induced 
cleavage, structural alteration, or interaction with autoreactive B cells.  
Immunoglobulin-snRNP complexes have been shown to be taken up by endocytosis 
through the B cell receptors on B cells or Fc-receptor on dentritic cells (Boule et al., 
2004; Leadbetter et al., 2002).  RNA components, particularly those rich in uridine (U) 
or uridine and guanosine (UG) function as effective l gands for Toll-like receptor TLR7 
and TLR7/8 in B cells and dentritic cells (Diebold et al., 2004; Heil et al., 2004; Vollmer 
et al., 2005).  TLR stimulation leads to cell activa on and proliferation, cytokine 
production, MHCII and co-stimulatory molecule expression, thus perpetuating 
autoimmunity (Martin and Elkon, 2005).  
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Epitope tagging proteins of interest, widely used for affinity chromatography, 
western blotting, or immunofluorescence assays, has been a valuable tool for protein 
compositional, structural and functional studies (a described in the previous chapters).  
Interestingly, when we specifically modified the pre-mRNA splicing factor SART1 
(U4/U6U5-110K) by insertion of the TAP tag at its 3’ terminus, autoimmune 
phenotypes were observed in mice containing a TAP tag at both loci.  Only 
homozygotes exhibit several physical manifestations typical of mouse autoimmunity such 
as runting syndrome with ruffled hair, hunched back nd severe anal prolapse.  These 
mice also possess high serum IgG levels and increased numbers of MZ B cells.  
Histological examination showed disorganized red and white pulp centers and 
proliferation of lymphocytes in spleen.  Infertility assays showed increased 
inflammatory cell infiltration and apoptosis in germ cells of homozygote testes.  
Additionally, the serum from some homozygote knockin mice specifically recognized a 
~60kD nuclear antigen, whereas serum from normal mice were non-reactive to nuclear 
protein components.  These mice will serve as a valuable tool for the studies of 
mammalian autoimmune diseases, especially those resulting from the generation of 
autoantibodies against RNP components, as well as serving as a biochemical tool for 
spliceosome analysis in live mice. 
5.2 MATERIALS AND METHODS  
5.2.1 Quantitation of total serum immunoglobulin concentration 
Whole blood samples were collected from mice tails.  After centrifugation, the 
supernatant was removed and stored at –80°C or immediately tested using an ELISA 
assay for total serum IgG or IgM using a mouse IgG or IgM ELISA Quantitation kit 
(Bethyl Laboratories).  Microtiter plates were coated with goat anti-mouse IgG or IgM 
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affinity-purified Ab and incubated for 60 min.  Plates were washed with [50 mM Tris-
HCl (pH 8.0), 0.14 M NaCl containing 0.05% Tween 20] and each well was blocked with 
200 µl of [50 mM Tris-HCl (pH 8.0), 0.14 M NaCl, and 1% BSA] for 30 min.  100 µl of 
test samples and standards were added per well, and incubated for 60 min.  100 µl of 
horseradish peroxidase (HRP)-labeled goat anti-mouse IgG or IgM Fc-specific antibodies 
were added to each well and incubated for 60 min.  Plates were washed, developed for 
30 min with HRP substrate TMB (3, 3’, 5, 5’-tetramethylbenzidine), stopped with 100 µl 
2 M H2SO4, and read
 at 450 nm using a microtiter plate reader. 
5.2.2 Flow cytometry analysis  
Spleens were harvested from euthanized mice and washed with HBSS buffer 
(Sigma).  Tissues were passed through a 70 µm nylon cell strainer to prepare a single-
cell suspension.  Isolated cells from spleens were tr ated with RBC lysis buffer [0.5 M 
NH4Cl, 0.15 M Tris-HCl, (pH 7.65)] for 5 minutes at room temperature to remove red 
blood cells.  Cells were washed with HBSS buffer twice, harvesting at 1000 x g at 4˚C 
and resuspended in Hanks buffer (HBSS buffer with 2% FBS and 0.1% sodium azide) on 
ice.  Cells were counted using a hemocytometer and 2x106 cells were used for FACS 
analysis.  Cells were incubated with Fc-blocking (kindly provided by Dr. Ellen Richie, 
M.D. Anderson Cancer Research center) for 15 minutes on ice.  Spleen cells were 
stained with the following mAbs for 45 minutes: APC-conjugated anti-CD19, FITC-
conjugated CD21, Bio-conjugated CD23, followed by PE-conjugated streptavidin (BD 
Pharmingen).  The cells were then washed twice in Ha ks buffer and once with HBSS 
buffer before fixing with 2% paraformaldehyde.  Cells were analyzed on a BD 
FACScalibur instrument and data were analyzed using CellQuest Pro software. 
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5.2.3 Western blot analysis for detection of autoantibodies 
Proteins from cytoplasmic and nuclear fraction were xtracted from 2x107 mouse 
STO cells.  Cells were harvested by centrifugation, allowed to swell in TM buffer [10 
mM Tris-HCl (pH 7.5), 3 mM MgCl2] containing 0.2 mM PMSF, 1 µg/ml pepstatin, and 
1 µg/ml leupeptin on ice for 10 minutes and lysed with 25 strokes of a dounce 
homogenizer.  The nuclei were pelleted and the post-nuclear supernatant was designated 
as the cytoplasmic fraction.  The nuclear pellets were washed twice with TM buffer 
containing 0.1% NP-40 and resuspended in low salt buffer [30 mM Tris-HCl (pH 7.5), 
125 mM KCl, 5 mM MgCl2, 0.5% Triton-X100] followed by sonication.  Two pulses of 
20 seconds each with 1 minute rest intervals were used at maximum output.  Insoluble 
nuclear material was pelleted by centrifugation.  For western blot analysis, 5 µg of total 
proteins from cytoplasmic or nuclear extracts were loaded and resolved on 10% 
polyacrylamide gels, transferred to nitrocellulose m mbranes and blotted with serum 
(1:1000 dilution) from the indicated mice.  The secondary antibody used was HRP-
conjugated goat anti-mouse IgG and the signal was detected by enhanced 
chemiluminescence (Perkin Elmer). 
5.2.4 Histological analysis of spleen 
Mice were sacrificed at 3 months of age and spleens were fixed in 10% neutral-
buffered formalin.  Paraffin embedded tissue sections were cut and stained with 
hematoxylin and eosin.  Multiple sections were observed under light microscope for 
histological examination. 
5.2.5 Immunohistochemical staining of liver samples 
Mice were sacrificed at 3 months of age and livers were fixed in formalin 
solution.  To detect the presence of SART1-TAP proteins, the slides were incubated 
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with PAP antibodies at a 1:50 dilution overnight at 4˚C followed by addition of 
peroxidase substrate DAB for staining development. 
5.2.6 Histology and TUNEL assay of Testis 
Mice were sacrificed at 3 months of age and testes were fixed in Bouin’s solution.  
Sections (5 µm) of paraffin embedded tissues were evaluated for morphological changes 
via standard methods using periodic acid-Schiff’s-Hematoxylin (PAS/H).  Tissues were 
imaged using a Nikon E800 microscope equipped with a digital camera and captured 
using MetaMorph software (Downingtown, PA).  Terminal deoxynucleotidyl 
transferase-mediated digoxigenin-dUTP nick end labeling (TUNEL assay, ApopTagTM 
kit, Intergen, Purchase, NY) was used to detect apoptotic fragmentation of DNA in germ 
cells as previously described (Seaman et al., 2003).  The signal from digoxigenin-dUTP 
end-labeled DNA was detected with anti-digoxigenin-peroxidase antibody followed by 
addition of peroxidase substrate [0.05% diaminobenzidi e (DAB)].  TUNEL-positive 
germ cells were counted in each seminiferous tubule of the testis cross section.  The 
incidence of apoptosis, represented as the apoptotic index was defined as the percentage 
of seminiferous tubules containing 3 or more TUNEL-positive germ cells. 
5.2.7 Statistical analysis 
The data were subjected to the analysis of variance (ANOVA) to determine the 
statistical significance.  Total serum immunoglobulin concentrations and percentage of 
apoptosis are presented as mean ± standard error of the mean (SEM). 
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5.3 RESULTS 
5.3.1 Tagged SART1 protein localizes in the nucleus 
To demonstrate the functional expression of the TAP tag in the progeny mice, an 
immunohistochemistry assay was used to detect the presence of SART1-TAP using the 
PAP antibody.  In Figure 5.1, we show that the SART1-TAP proteins were localized in 
the nucleus of liver cells in SART1-TAP homozygotes.  As the wild-type mice did not 
contain SART1-TAP, no signal was detected indicating he specificity of detection in the 
mutant mice (Figure 5.1).   
 
 
 
 
 
 
 
 
 
 
 
 116 
 
 
Figure 5.1 Nuclear localization of SART1-TAP in homozygote mice. 
Formaldehyde fixed liver samples were sectioned, and immunohistochemistry was 
performed using the peroxidase-antiperoxidase (PAP) antibody as described in the 
Materials and Methods.  Wild-type samples did not exhibit SART1 signal, while 
homozygote mice possess nuclear-localized SART1-TAP (arrows) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 117 
 
Figure 5.2 Phenotypes of SART1-TAP homozygotes. 
The SART1-TAP homozygotes are smaller compared to their littermates (left panel) with 
ruffled hair (middle panel) and anal prolapse (right panel) symptoms. 
 
5.3.2 Phenotypes of the SART1-TAP homozygotes 
Seven out of sixteen SART1-TAP homozygotes were proportional dwarfs 
compared to their littermates and three died at the age of 4 months.  The accompanying 
phenotypes include hunched back, ruffled hair, prolapsed anus and infertility (Figure 
5.2).  Runting syndrome is usually associated with an underlying immunological 
etiology, such as graft-versus-host reaction, neonatal thymectomy, cortisone injection 
into neonates, bacterial vaccine or endotoxin injection into neonates, and neomycin 
sulphate treatment (Keast, 1968).  Although the severity of the clinical phenotypes in 
homozygotes is exhibited to different degrees in each individual, the combination of 
these phenotypes suggests an abnormal immunologic response in the SART1-TAP 
homozygotes.  We feel the differences in severity are probably due to differential 
penetrance of the effects of the modification or individual susceptibility to the 
modification, similar to that seen in human autoimmunity patients. 
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5.3.3 Increased total serum IgG in SART1-TAP homozygotes 
Total serum IgG levels were determined in wild-type, heterozygote- and 
homozygote-modified SART1 mice.  In homozygotes, serum IgG levels were twice, on 
average, the IgG levels in WT mice (Figure 5.3).  We note that the IgG concentration is 
correlated to the clinical phenotype; the more severe the phenotypes, the higher the total 
serum IgG concentration.  This effect is not due to an overall increase in the levels of 
total immunoglobulin, however, as there is no signif cant difference in the total serum 
IgM concentration between the WT, heterozygotes, and homozygotes (Figure 5.4). 
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Figure 5.3 Serum IgG levels in wild-type and SART1-TAP homozygotes.   
Serum IgG levels in SART1-TAP homozygote mice on aver ge were twice that of the 
wild-type or SART1-TAP heterozygote mice (*P< 0.05 between WT and homozygotes).  
When SART1-TAP homozygote mice were compared based on the severity of the 
phenotypes, IgG levels were higher in mice with more severe phenotypes (cf. Anal 
prolapse with ruffled-hair only or no phenotype).  Data are presented as ± S.E.M. 
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Figure 5.4 Serum IgM levels in wild-type and SART1-TAP homozygotes.  
Serum IgM levels in wild-type mice were indistinguishable from that of SART1-TAP 
heterozygote or SART1-TAP homozygote mice.  Data are presented as ± S.E.M. 
 
 
5.3.4 Disorganized spleen tissue in SART1-TAP homozygotes 
Typically, the organization of the spleen includes two major features termed red 
pulp and white pulp.  The function of the red pulp is to filter out damaged red blood 
cells from circulation and the white pulp is a site rich in B-cells and T-cells.  In wild 
type mice, these centers have defined boundaries (Figure 5.5).  In SART1-TAP 
homozygotes, however, histopathological differences in pleen organization were noted, 
with smaller centers of red and white pulp and general disorganization (Figure 5.5).  
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Figure 5.5 Spleen disorganization in SART1-TAP homozygotes.   
Sectioned spleen from a wild-type mouse showed normal organization of red and white 
pulp in the left panel.  Sectioned spleen from a SART1-TAP mouse showed overall 
histopathological disorganization and smaller centers of red and white pulp in the right 
panel. 
 
 
 
5.3.5 Increased MZ B cells in SART1-TAP homozygotes 
Marginal zones are regions in the spleen between th red pulp and the white pulp.  
Unlike circulating B cells, MZ B cells are static, and never leave this region.  MZ B 
cells contain relatively high levels of the cell surface marker CD21 and relatively low 
levels of the CD23 marker protein (CD21hiCD23lo).  Studies have shown MZ B cells are 
enriched with self-reactive clones - for example, MZ B cells are increased in the lupus-
prone mice, suggesting an important role in initiation of autoimmunity.  The marginal 
zone B cells of wild-type and SART1-TAP homozygotes were compared.  In the 
SART1-TAP homozygote mice the MZ B cells were >2 fold higher compared to those in 
wild-type siblings, indicating an enrichment of self-r active clones (Figure 5.6). 
 
 
 122 
 
 
 
Figure 5.6 Marginal zone B-cells in wild-type and SART1-TAP homozygotes.   
CD21 and CD23 were assayed in single-cell suspensions fr m spleens of wild-type and 
SART1-TAP homozygotes.  Left panel: wild-type mice ontain 2.03% CD21hiCD23lo 
cells, indicative of the marginal zone B-cell population.  Right panel: SART1-TAP 
homozygotes have 4.19% CD21hiCD23lo cells, a greater than two-fold increase of this 
population. 
 
 
5.3.6 Infertility accompanies the autoimmune phenotypes  
Attempts to mate homozygote males and females were unproductive, indicating 
potential infertility problems in these mice.  We examined the morphology and 
apoptosis status of the germ cells in wild-type andSART1-TAP homozygote testes.  In 
WT mice, the germs cells aligned regularly in the seminiferous tubules and the tubules 
were uniform in size and shape.  Cells in the center of the seminiferous tubules are more 
mature, with the immature cells at the periphery.  In SART1-TAP homozygotes, the 
seminiferous tubules have an abnormal and irregular sh pe with various lumen sizes and 
the cells are aligned randomly in the tubules indicating maturation defects (Figure 5.7).  
WT Homozygote 
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The apoptosis level in these mice was assessed by the TUNEL assay (Figure 5.8).  In 
addition, infiltration of macrophages was observed in the interstitial tissue of the testis of 
homozygotes (circled in Figure 5.8).  The apoptotic index was calculated as the number 
of seminiferous tubules with 3 or more apoptotic cells (Figure 5.9).  The apoptotic level 
of the homozygotes was significantly higher than that of the wild type mice. 
We also examined the reproductive organs of female SART1-TAP homozygotes. 
Female homozygotes have much smaller uteri, fallopian tubes, and ovaries compared to 
those in wild-type mice, suggesting they suffered from failure of normal development of 
these organs (Figure 5.10).  These organs were harvsted for histology analyses. 
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Figure 5.7 Testes histology of wild-type and SART1-TAP mice.   
Sections of seminiferous tubules from wild-type (top panel), heterozygote (middle panel) 
or homozygote (bottom panel) mice were fixed in Bouin’s solution and stained with 
periodic acid-Schiff’s-hematoxylin.  The morphology in wild-type is normal with 
immature cells at the periphery of the tubules and mature cells in the lumen.  In contrast, 
the cells in the seminiferous tubules from homozygotes are disorganized with various 
lumen size of the tubules. 
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Figure 5.8 Apoptotic defects in SART1-TAP homozygotes.  
Darker regions represent apoptotic cells in this assay.  A gradient of apoptotic severity is 
seen between wild-type (top panel), heterozygote (middle panel) and homozygote 
(bottom panel) mice.  Presumptive macrophages are shown circled and indicate likely 
infiltrative immune responses. 
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Figure 5.9 Apoptotic index in wild-type and SART1-TAP mice.  
The numbers of seminiferous tubules in SART-TAP homozygotes undergo apoptosis 4 
times more than those in wild-type mice (* P< 0.05, data are presented as ± S.E.M.). 
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Figure 5.10 Gross view of uterus from wild-type and SART1-TAP homozygotes. 
Uteri (arrows) and kidneys (K ) were noted.  Compared to the wild-type mice 
(left panel), the uterus in homozygotes (right panel) was much smaller, indicating failure 
to develop. 
 
 
5.3.7 The presence of antinuclear antibodies in SART1-TAP homozygotes serum 
In several forms of autoimmune disease, a spectrum of antibodies to RNP 
components, such as anti-Sm, anti-U1 RNP, anti-Ro/SSA, and anti-La/SSB has been 
seen.  Using serum as a primary antibody source, we not d a signal of approximately 
60Kd in the nuclear fraction in SART1-TAP homozygotes (Figure 5.11), showing that in 
addition to the array of autoimmune symptoms discused above, SART1-TAP 
homozygotes produce anti-nuclear autoantibodies in much the same way as classical 
autoimmune mice do. 
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Figure 5.11 Circulating anti-nuclear antibodies in SART1-TAP homozygotes.   
Serum from wild-type and SART1-TAP mice was used as a primary antibody in a 
western blot against total protein from the nuclear (N) or the cytoplasmic (C) fractions of 
cultured murine cells.  After probing with a secondary, anti- mouse IgG antibody, a 
~60kD antigen present exclusively in the nucleus wareactive with serum from only the 
SART1-TAP homozygote mice.   
 
 
5.4 DISCUSSION 
Autoimmune diseases are characterized by circulating autoantibodies reactive 
against cellular components.  Among the earliest identified antibodies were anti-Sm and 
anti-U1 snRNP antibodies, targeting conserved nuclear components (Mattioli and 
Reichlin, 1971; Tan and Kunkel, 1966).  Lerner and Steitz showed that anti-Sm 
antibodies react with the U1, U2, U4 and U5 snRNP particles whereas anti-U1 snRNP 
antibodies precipitate only the U1 snRNP (Lerner and Steitz, 1979).  Subsequently, they 
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showed that the sequence of U1 RNA is complementary to 5’ splice junctions in pre-
mRNA, providing a link between snRNPs and pre-mRNA splicing (Lerner et al., 1980). 
The question of how autoantigens stimulate inappropriate immune response has 
remained mysterious for several decades now.  The SmB/B’ protein possesses an 
epitope PPPGMRPP (Williams et al., 1990), located within its carboxyl-terminus, which 
cross-reacts with the U1 snRNP (De Keyser et al., 1992), suggesting similarities in 
autoimmune response generation (Arbuckle et al., 1999). 
Proper folding and posttranslational modifications of the epitope have also been 
shown to be important for autoimmune responses.  Methylation of arginine residues 
within the C-terminal epitope of SmD1 is critical for the recognition of SmD1 by anti-Sm 
antibodies (Brahms et al., 2000).  In contrast, synthetic SmD1 peptides produced in vitro 
or SmD1 overexpressed in E. coli interact only weakly or non-specifically with anti-Sm 
antibodies (Rivkin et al., 1994; Rokeach et al., 1992).  Interaction between anti-La/SSB 
antibodies and La proteins is strongly dependent on phosphorylated La protein at its 
serine 366 residue (Terzoglou et al., 2006a) whereas anti-Ro antibodies preferentially 
recognize the unmodified Ro protein (Terzoglou et al., 2006b).  In addition, the 
antigenicity of Ro is significantly enhanced upon bi ding with a chaperone protein, 
calreticulin (Staikou et al., 2003).  Although little is known about the effects of the 
modification of proteins on its antigenicity, modification of the SART1 protein by 
insertion a TAP tag at its 3’ terminus may change its structure, and provoke 
autoimmunity.  
 Several studies have shown the links between apoptosis and autoimmunity (Utz 
et al., 2000).  Novel epitopes generated during apoptosis, produced either by altered 
peptide structure or residue modification, are sequestered in apoptotic blebs of the cell 
(Casciola-Rosen et al., 1994), and are proposed to serve as targets for autoantibody 
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production (Casciola-Rosen et al., 1994; Hall et al., 2004; Hof et al., 2005; Utz et al., 
1997).  Failure of completion of apoptosis or the clearance of apoptotic cells can lead to 
autoimmunity by exposing novel epitopes to the immune system (Kim et al., 2003; Utz et 
al., 2000). Consistent with view, germ cells with a high apoptotic index are found in 
SART1-TAP tagged homozygotes.  These apoptotic cells may result from delays in 
programmed cell death or failure to clear apoptotic cells.  These apoptotic cells may be 
triggering autoantibody production in these mice. 
In conclusion, modification of the SART1 protein with a TAP tag, and defects in 
apoptosis pathways may contribute to the autoimmune response in SART1-TAP tagged 
homozygotes.  We would like to note that the anti-nuclear antibodies do not recognize 
the 130kD SART1-TAP, and thus the autoimmune respone is directed against factors in 
the nucleus unrelated to the modification generating he response.  Whether this is a 
common feature in autoimmune pathology remains to be seen.  Our homozygote 
SART1-TAP mice provide a new model for studying thepathology of autoimmunity, 
especially those resulting from the generation of auto ntibodies against RNP 
components.   
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Appendix 
Appendix A Validation of matched polypeptides by the number polypeptides identified and 
the percentage of the polypeptide covered 
    Chicken   Human   
   polyspliceosome  polyspliceosome 
ENSEMBL accession # Polypeptide 
# pep. 
ID 
% 
coverage 
# pep. 
ID 
% 
coverage 
U1 snRNP      
ENSG00000104852 U1-70K 11 38.3 4 12.1 
ENSG00000077312 U1A 6 24.3   
      
U2 snRNP      
ENSGALG00000008038 SF3b155 35 32.2 26 28.8 
ENSG00000087365 SF3b145 12 15.5 9 9.6 
ENSGALG00000002531 SF3b130 23 26.1 14 14.5 
ENSGALG00000000581 SF3b125 5 18 3 12.5 
ENSGALG00000007937 SF3a120 21 30.1 10 21.9 
ENSGALG00000021679 SF3a66 5 28.3 4 19.2 
ENSGALG00000001540 SF3a60 14 29.1 9 24.4 
ENSGALG00000013352 SF3b49 3 21.7   
ENSGALG00000008729 U2B" 8 29.2 4 23.1 
ENSGALG00000007170 U2A' 10 43.9 8 35.3 
ENSGALG00000016501 SF3b14 5 36   
ENSGALG00000020000 SF3b10 2 22.1   
      
U2-snRNP associated      
ENSGALG00000014395 PRP43/DDX15 25 31.6 13 19 
ENSGALG00000002612 SR140 12 13.7 5 5.6 
ENSGALG00000006332 SPF45 8 23.4   
ENSGALG00000008561 SPF30 3 15.3   
ENSGALG00000003824 CHERP 3 5   
      
U5, U4/U6 & U4/U6•U5 snRNP     
ENSGALG00000002943 U5-220K 72 33.7 41 21 
ENSGALG00000003477 U5-200K 63 27.8 44 26.8 
ENSGALG00000000988 U5-116K 31 34.7 22 33.3 
ENSG00000175467 U4/U5•U5-110K 2 5.1 12 19.2 
ENSGALG00000006001 U5-102K 31 19.5 21 27.3 
ENSG00000174243  U5-100K 21 29.9 18 26.4 
ENSGALG00000000465 U4/U6-90K 13 25 8 24.6 
ENSG00000168883   U4/U6•U5-65K 4 12.9 6 14.8 
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(Continued) 
    Chicken   Human   
   polyspliceosome  polyspliceosome 
ENSEMBL accession # Polypeptide 
# pep. 
ID 
% 
coverage 
# pep. 
ID 
% 
coverage 
ENSG00000105618 U4/U6•U5-61K 5 20.1 8 23 
ENSGALG00000008857 U4/U6-60K 12 28.7 7 16.1 
ENSGALG00000004874 USA-CYP 2 24.1   
ENSGALG00000000615 U5-40K 10 33.5 5 23.2 
ENSGALG00000011931 U4/U6•U5-15.5k 2 12.4   
ENSGALG00000017396 U5-15K 2 16.2   
      
AT/AC      
ENSGALG00000005162 U11/U12-65K 2 8.6   
ENSGALG00000013005 U11/U12-48K 2 7.2   
      
Sm/LSM      
ENSGALG00000007250 SmB/B' 9 40.2 5 40.7 
ENSGALG00000011842 SmD1 4 37.8 4 54.6 
ENSG00000125743 SmD2 12 13.7 5 44.9 
ENSGALG00000006596 SmD3 4 47.6 5 40.7 
ENSGALG00000000137 SmE 5 79 2 19.8 
ENSGALG00000011409 SmF 4 8.7 2 15.1 
ENSG00000143977 SmG 3 31.3 3 35.5 
ENSG00000111987 LSM2 3 39   
ENSGALG00000003385 LSM4 3 31   
ENSGALG00000009985 LSM6 3 35 3 36.3 
ENSGALP00000014820 LSM8 3 52.1 2 34.3 
      
snRNP biogenesis      
ENSGALG00000010154 SIP1  4 14.7   
ENSG00000119953 SMNrp30 2 6   
ENSGALG00000003158 Coilin 8 20.2   
      
SAPs      
ENSGALG00000002514 PSF 8 16.8 12 19.1 
ENSGALG00000002060 TLS/FUS 10 15.7 3 13.7 
ENSGALG00000012468 PRP39 4 9.8   
ENSGALG00000010501 SKIP/PRP45 16 38.8 2 10.8 
ENSGALG00000016704 CDC5 24 37.7 11 16.3 
ENSGALG00000005012 ISY1 4 20   
ENSGALG00000008429 CRN1 15 24.5 4 6 
ENSGALG00000009257 Prp46/PRL1 15 38.6   
ENSGALG00000015061 CDC40/PRP17 15 39.3     
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    Chicken   Human   
   polyspliceosome  polyspliceosome 
ENSEMBL accession # Polypeptide 
# pep. 
ID 
% 
coverage 
# pep. 
ID 
% 
coverage 
ENSGALG00000002002 SPF27 4 27 3 12.5 
ENSGALG00000013919 PRP19 13 35.4 15 46 
ENSGALG00000010627 PRP38 5 18.3 3 15.6 
ENSGALG00000005507 p54nrb 5 14.4 5 13.2 
ENSGALG00000004555 ECM2/RBM22 6 18.6   
ENSGALG00000001247 SYF2 4 8.7   
ENSGALG00000000726 ELAV/Hu 4 13.8 11 48.2 
ENSGALG00000009001 CWC22 7 9.5   
ENSGALG00000008149 EWSR1 (RBP) 5 10 2 9.9 
ENSGALG00000004705 BUD31 2 27.3   
ENSG00000076924 SYF1 15 21.1 13 20.9 
ENSGALG00000001962 PTB 12 32.5 12 19.1 
ENSGALG00000011857 LUC7/CROP 3 30.7   
ENSG00000196504 PRP40 3 4.2 2 4.5 
ENSGALG00000010167 Pinin 14 23 10 16.2 
ENSGALG00000012813 Prp4K 6 16.1 8 25.2 
ENSGALG00000000833 RED 7 12.4 7 21.4 
ENSGALG00000001500 SLU7 8 15.4   
ENSG00000063244 U2AF65 2 10.1 7 31 
ENSGALG00000016198 U2AF35 2 14.6 3 16.9 
ENSGALG00000001034 AAR2 5 15.1   
ENSGALG00000005525 SF2/ASF 4 20.3 3 30.6 
ENSGALG00000002087 CBC80 3 3.5 12 37.7 
ENSGALG00000006843 CBC20 3 28 2 15.1 
ENSG00000100296 KIAA0983 5 11.3 2 6.1 
ENSG00000126803 HSP70-2 5 14.8 6 10.4 
ENSGALG00000006512 HSP71 22 38.8 4 6.1 
ENSGALG00000009838 Aquarius 25 17.5 20 22 
ENSGALG00000002014 SMU1 10 33.1 4 19.1 
ENSG00000113649 CA150   4 12.1 
ENSGALG00000004626 E1B-AP5 6 11.2 5 10.1 
ENSGALG00000011678 DnaJ 8 8.3 4 5.6 
ENSG00000100813 Acinus   10 22.6 
ENSG00000131051 HCC   9 27.3 
ENSG00000084463 WBP11   2 4.5 
ENSG00000196419 Ku70   8 16.4 
      
RNA Helicase-like      
ENSGALG00000016461 DDX1 10 18.6 8 16.4 
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    Chicken   Human   
   polyspliceosome  polyspliceosome 
ENSEMBL accession # Polypeptide 
# pep. 
ID 
% 
coverage 
# pep. 
ID 
% 
coverage 
ENSGALG00000016231 DDX3 5 10.3 9 17.4 
ENSGALG00000003532 DDX5/p68 16 28.9   
ENSGALG00000012247 DDX17/p72 11 20.8 13 21.3 
ENSGALG00000012147 DDX18 2 10   
ENSGALG00000006974 DDX27 3 5.1   
ENSGALG00000003030 DDX41/ABSTRAKT 3 7.4   
ENSG00000123136 DDX39   12 34.9 
ENSG00000145833 DDX46/PRP5   13 19 
ENSGALG00000008530 DDX48 18 48.4 15 39.7 
ENSGALG00000004144 DDX50/Gu-ß 2 3.8 11 17.3 
ENSGALG00000001186 DHX8/PRP22 12 17.9 2 7.7 
ENSG00000135829 DHX9/HELICASEA 3 5.6 43 40.9 
ENSGALG00000005027 DHX30 20 19.7 9 9.3 
ENSGALG00000003658 DHX35 4 7.8   
ENSG00000174953 DHX36   5 5.1 
ENSGALG00000014709 SKIV2L2 5 7.1 2 10.8 
ENSG00000198563 UAP56 12 29.7 12 34.9 
      
hnRNP      
ENSGALG00000006160 hnRNPA0 4 10.2 7 35.4 
ENSGALG00000011036 hnRNPA2/B1 12 37.8 23 67.2 
ENSG00000135486 hnRNPA1 7 32.7 26 52.9 
ENSGALG00000009250 hnRNPA3 11 42.9 19 51.6 
ENSGALG00000014381 hnRNPAB 6 20.7 7 22.1 
ENSG00000092199 hnRNPC1/C2 10 32.5 14 47.9 
ENSG00000138668 hnRNPD0/AUF1 4 29.7 13 45.6 
ENSGALG00000011184 hnRNPD0 4 20.6 9 25.4 
ENSG00000169813 hnRNPF   12 42.4 
ENSGALG00000006457 hnRNPG 15 34.3 11 26.9 
ENSGALG00000005955 hnRNPH1 17 46.4 13 40.3 
ENSGALG00000003947 hnRNPH3 12 13.7 6 26.9 
ENSGALG00000012591 hnRNPK 18 46.1 18 49.1 
ENSG00000104824 hnRNPL 7 13.7 14 33 
ENSGALG00000000377 hnRNPM 24 38.6 21 37.7 
ENSGALG00000015830 hnRNPQ 10 27.3 18 45.8 
ENSGALG00000000814 hnRNPR 11 22.5 21 42.1 
ENSGALG00000010671 hnRNPU 10 13.1 29 33 
ENSGALG00000018665 hnRNP novel 2 ***   
ENSG00000126457 HRMT1L2  2 11.5     
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SR      
ENSGALG00000005525 SF2p33 9 35.8 12 37.9 
ENSGALG00000000533 SFRS3SRp20 3 24.4 8 59.3 
ENSGALG00000009484 SRp40 5 24.8   
ENSGALG00000000990  SRp55 6 27.4 4 11.5 
ENSGALG00000013825 9G8 5 26 6 37.6 
ENSGALG00000002487  SFRS8 6 10.5   
ENSG00000111786 SRp30   8 37.6 
ENSGALG00000006531 SFRS10 4 20.1 6 37.2 
ENSG00000153914 SFRS12   3 11.9 
ENSGALG00000004133 SRrp35 3 37.1 6 41.8 
      
RBP      
ENSG00000102317 RBM3   25 5.6 
ENSGALG00000018992 RBM4B/Lark 9 56.8   
ENSGALG00000004626 RBM5 4 9.1   
ENSGALG00000007017 RBM7 3 36   
ENSG00000131795 RBM8B 3 17.7 4 31 
ENSGALG00000013411 RBM14 6 12.9 8 15.7 
ENSG00000162775 RBM15   7 12 
ENSGALG00000002372 RBM15B 7 15.6 3 8.5 
ENSG00000197676 RBM16   8 12.3 
ENSGALG00000004555  RBM22 5 17.4   
ENSG00000119707 RBM25   4 8.4 
ENSG00000091009 RBM27   2 3.2 
ENSGALG00000011038 RNPS1 3 17   
ENSG00000033030 ZFP8   6 8.1 
ENSGALG00000006113 ZFP326 10 23.2 2 9.4 
ENSG00000179950 PUF60   3 10.9 
ENSG00000197381 ADAR1   26 33.7 
ENSG00000160710 ADAR2   4 10 
ENSGALG00000010952 Requiem 12 27.2   
ENSGALG00000011570 NFAT45 8 21.4 12 53.7 
ENSG00000129351 NFAT90 10 15.5 12 18.4 
ENSG00000169564  PolyrCBP 7 28.7   
ENSGALG00000012225 CIRBP 2 24.5 3 18.9 
ENSG00000056097 ZFR 2 3.4 3 8 
ENSGALG00000009427 TIA1 2 8.8   
ENSGALG00000001187 STRBP 10 18.5     
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ENSGALG00000005623  Tuftillin-IP 8 12.4 5 6.7 
ENSG00000136231 IMP3 4 7.5 7 18.9 
ENSG00000121774 SAM68   4 10.2 
ENSG00000126254 Novel RRM   3 14 
ENSG00000132773 TOE1   2 6.7 
ENSG00000142864 SERBP1   2 9.1 
      
Export/transcription/NMD     
ENSGALG00000014915 THO1/HPR1 11 26 6 14.6 
ENSGALG00000008507 THO2 14 9.7 5 8 
ENSG00000051596 THO3/TEX1 14 24.2 13 16.3 
ENSGALG00000007237 THO4/ALY 6 20.9 8 30.8 
ENSGALG00000004571 GLC7/PPP1CA 2 5.3   
ENSGALG00000002569 Ran 5 30.1 2 4.8 
ENSG00000119392  GLE1L   2 5.7 
ENSGALG00000007653 GLE2/RAE1 3 8.4 7 13.1 
ENSGALG00000003220 UPF1/RENT 3 6.4   
ENSG00000131795 Y14/RBM8A 4 36.2 4 31 
ENSGALG00000002144 TRAP150 9 20.9 3 24.3 
ENSG00000172660 TAF15/RBP56 4 9.2   
ENSG00000162231 TAP   7 13.1 
ENSG00000065978 YBX1   5 33.5 
ENSGALG00000010689 Mago nashi 7 52.8 7 57.9 
      
3' end proc.      
ENSGALG00000010783  CPSF2 2 10.5   
ENSGALG00000016424 CPSF3 2 8.1 2 4.8 
ENSGALG00000004714 CPSF4 4 20   
ENSGALG00000003084 CPSF5   4 21.6 
ENSGALG00000011685 CSTF-77 3 4.5 3 6.2 
ENSGALG00000013943 FIP1 4 7.8   
ENSG00000172239 PAIP1   5 14.2 
ENSG00000100836 PABPN1   5 16.9 
ENSGALG00000003800 PABPC4   10 22.6 
      
Structural      
ENSGALG00000012533 Myosin 44 28.4 26 32.8 
ENSGALG00000009126 Titin 12 ***   
ENSGALG00000001381 Actin 15 52 3 17.6 
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ENSGALG00000002478 MATRIN3 17 24.2 28 34.2 
ENSGALG00000008677 Vimentin 13 40.1 24 50.7 
ENSG00000117245 Kinesin KIF17 7 8   
ENSGALG00000002197 NUMATRIN 4 17 4 4.5 
ENSGALG00000014692 Lamin B 18 35.8 4 9.9 
ENSGALG00000013505 NuSpectrin 12 *** 34 19.9 
      
Chromatin 
modification      
ENSGALG00000000360 ARID1A-SWI/SNF 18 27.4   
ENSGALG00000013683 ARID1B-SWI/SNF 13 9.8   
ENSGALG00000010164 SMARCA2 27 33.4   
ENSG00000127616 Brahma/SMARCA4 29 21.3   
ENSGALG00000009913 SMARCA5 11 11   
ENSGALG00000005983 SMARCB1 11 37   
ENSGALG00000005048 BRG1-SWI/SNF 30 20.2   
ENSGALG00000005048 SMARCC1 21 19.5   
ENSGALP00000010010 SMARCD1 6 11.5   
ENSGALG00000000363 SMARCD2 10 32.9   
ENSGALG00000002100 SMARCE1 7 30.9   
      
Nucleoporins      
ENSGALG00000005714 PKD1 (NUP assoc) 10 4.1   
ENSGALG00000003830 NUP214 7 4.8 4 4 
ENSGALG00000012720 NUP153 4 4.3   
ENSGALG00000005078 NUP210 6 4.9 8 5.1 
ENSG00000102900 NUP93   19 29.4 
ENSG00000108559 NUP88   8 13.9 
ENSG00000111581 NUP107   5 31.3 
ENSG00000110713 NUP98   4 11.9 
ENSG00000138750 NUP54   4 21.3 
ENSG00000163002 NUP35   3 14.6 
ENSG00000069248  NUP133   3 3.4 
ENSG00000155561 NUP205   4 3.3 
      
Cyclophillins      
ENSGALG00000013383 CYP-E 4 20.4   
ENSGALG00000004874 USA-CYP 2 34.1   
ENSGALG00000014747 CYP16 4 12.4   
ENSG00000137168 PPIL1/CWF27 2 12.2     
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ENSG00000100023 PPIL2/CYP60 2 6.1   
ENSG00000113593 PPWD1 4 7.4   
      
Novel or unknown to splicing     
ENSGALG00000011351 HSP90a 11 18.2 10 19.3 
ENSGALG00000010175 HSP90ß 18 23.4 9 14.6 
ENSGALG00000012726 HSP108 15 19 8 14.5 
ENSGALG00000009967 LRP130 19 13.5   
ENSGALG00000003693 Macrophin 6 16.9   
ENSGALG00000007705 Nucleolin 10 16.4   
ENSGALG00000015933 GCRBF 3 5.9   
ENSGALG00000008454 NOP58 5 12.5   
ENSGALG00000009061 BAF53A 9 32   
ENSGALG00000007520 FACT80 9 13.8 3 5.6 
ENSGALG00000015821 TCP1-theta 7 15.9   
ENSGALG00000014500 Nol5A/NOP56 9 19.4   
ENSGALG00000005624 TRAP230 2 4.6   
ENSGALG00000010973 TRA2a 4 20 2 16.8 
ENSGALG00000008372 RAT1 8 10 3 3.7 
ENSG00000197157 SND1 5 8.8 16 25.9 
ENSGALG00000001948  SAFB/HSP27 3 8.2 12 78.9 
ENSGALG00000003177 BRD8 4 *** 2 6.9 
ENSGALG00000010699 FOG 3 ***   
ENSGALG00000005177 C9ORF10 4 6.8 3 5 
ENSGALG00000002653  ELG 4 13.2 3 8.7 
ENSGALG00000016949 WBP4 5 14.4   
ENSGALG00000004133 Fus IP 3 37.1 6 41.8 
ENSGALG00000017384  ERH 3 65.6 3 33.3 
ENSG00000079246 Ku80   14 28.1 
ENSG00000182562 ATAD3A 12 24.4 9 18.6 
ENSGALG00000001515 ATAD3B 10 19 6 21.3 
ENSG00000108588  CCDC47     2 18.4 
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